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This review focuses on the application of nanomaterials for neural interfacing.
The junction between nanotechnology and neural tissues can be particularly
worthy of scientific attention for several reasons: (i) Neural cells are electro-
active, and the electronic properties of nanostructures can be tailored to match
the charge transport requirements of electrical cellular interfacing. (ii) The
unique mechanical and chemical properties of nanomaterials are critical for
integration with neural tissue as long-term implants. (iii) Solutions to many
critical problems in neural biology/medicine are limited by the availability of
specialized materials. (iv) Neuronal stimulation is needed for a variety of
common and severe health problems. This confluence of need, accumulated
expertise, and potential impact on the well-being of people suggests the
potential of nanomaterials to revolutionize the field of neural interfacing. In this
review, we begin with foundational topics, such as the current status of neural
electrode (NE) technology, the key challenges facing the practical utilization of
NEs, and the potential advantages of nanostructures as components of chronic
implants. After that the detailed account of toxicology and biocompatibility of
nanomaterials in respect to neural tissues is given. Next, we cover a variety of
specific applications of nanoengineered devices, including drug delivery, ima-
ging, topographic patterning, electrode design, nanoscale transistors for
high-resolution neural interfacing, and photoactivated interfaces. We also
critically evaluate the specific properties of particular nanomaterials—including
nanoparticles, nanowires, and carbon nanotubes—that can be taken advantage
of in neuroprosthetic devices. The most promising future areas of research and
practical device engineering are discussed as a conclusion to the review.
 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1. Introduction
The field of nanomaterials offers to have a
particularly high impact onmedicine.[1–4] It is
thus appropriate to assess the current state
and projected future role of nanotechnology
within relevant areas of biomedical science
and engineering. Interfacing with neural
tissues, for example, is an especially challen-
ging problem that is unsolved by current
technologies. There exists a wide range of
health problems that can be treated by
stimulation of the nervous system, including
hearing loss, chronic pain, incontinence,
obesity, and diabetes. Some of these pro-
blems, such as paralysis or retinal degenera-
tion, are exceptionally hard to treat. At the
same time, the set of medical devices and
treatments available to a practitioner in this
field for evaluating and treating disorders
related to neural tissues is especially limited.
This situation is caused in part by the poor
accessibility of most of the nervous system
and by insufficient development of methods
to intercept and alter the transmission of
neural signals.[3] In the larger sense, interfa-
cing with neural tissue also involves the tasks
of its monitoring and drug delivery, which
are also often more challenging than for
other tissues. The combination of theseS. Campidelli
rmaceutical Sciences, University of Trieste
34127 Trieste (Italy)
ts.it
onda, I. P. Clements
medical Engineering
f Technology, Atlanta, GA (USA)
gatech.edu
r. S. Pathak
oengineering, Ophthalmology, and Neurosciences
y of California, San Diego, CA (USA)
d.edu
Prof. L. Ballerini
ysiology and Pathology, Center for Neuroscience
ty of Trieste, via Fleming 22, 34127 Trieste (Italy)







Nicholas A. Kotov earned his B.S.
(1987) and Ph.D. (1990) degrees from
Moscow State University. After a post-
doc at Syracuse University he assumed
an Assistant Professor position at
Oklahoma State University. At OSU
Kotov pioneered the studies of
self-organization of nanoparticles and
layered composites from nanocolloids. In 2003, he moved to
the University of Michigan to become a Professor at the
Departments of Chemical Engineering, Materials Science,
and Biomedical Engineering. In Michigan, Kotov developed
several biological applications of nanoparticles and
nanocomposites with strong emphasis on neural interfaces.
He also works on advancing understanding the fundamental
similarities between nanoscale and biological systems.
Jessica O. Winter received her Ph.D. in
Chemical Engineering from the University
of Texas at Austin in 2004. She completed
a post-doc fellowship at the Center for
Innovative Visual Rehabilitation, a colla-
borative effort between the Boston VA
Hospital, HarvardMedical School, and the
Massachusetts Institute of Technology to
develop a retinal prosthesis. Since
summer 2006 Winter is an Assistant Professor in the
departments of Chemical and Biomolecular Engineering (and
Biomedical Engineering) at the Ohio State University. Her
current research interests include the development of
biomimetic materials to improve the electrode/host interface in
stimulating prostheses and the development of multi-functional
nanoparticles for biological manipulation and imaging.
Charles M. Lieber received his Ph.D. in
Chemistry at Stanford University followed
by postdoctoral research at the California
Institute of Technology, he assumed an
Assistant Professor position at Columbia
University. There Lieber studied the
synthesis and properties of low-
dimensional materials. He moved to
HarvardUniversity in 1991 and now holds a joint appointment in
the Department of Chemistry and Chemical Biology, as the Mark
Hyman Professor of Chemistry, and the School of Engineering
and Applied Sciences. At Harvard, Lieber has pioneered the
synthesis of a broad range of nanoscale materials, the
characterization of the unique physical properties of these
materials and the development of methods of hierarchical
assembly of nanoscale wires, together with the demonstration of
applications of these materials in nanoelectronics, nanocom-
puting, biological and chemical sensing, neurobiology, and
nanophotonics. Lieber has also developed and applied a new
chemically sensitive microscopy for probing organic and
biological materials at nanometer and molecular scales.issues motivated us to undertake this work in order to highlight the
large number of successes in this field, as well as to address critical
problems and challenges that face the field as it continues to move
forward.
Until recently the development of neural prosthetic devices
for recording and stimulation was primarily fueled by advances
in microscale processing of silicon and other electronics-related
materials. There were a number of excellent review articles
focused on microscale technologies applied to neural electrodes
(NEs).[5–11] In this work, the focus is nanotechnology and
nanomaterials for the same applications. Nanostructures
represent a significant and largely untapped resource for the
diagnosis and treatment of injuries and diseases related to
neural tissues. From the point of view of a cell biologist, the
complex electrical properties and nanoscale structural features
of neural tissue necessitate a neural interface with nanoscale
components. Nanoengineered materials and devices have the
potential to interact with biological systems on a molecular
scale, offering unprecedented levels of control over physiological
activity. Indeed, many elements of cell machinery, such as ionic
channels, adhesion proteins, filopodia, signal proteins, inter-
facial topography of cell membrane, and elements of cytoske-
leton all have nanoscale dimensions, and materials engineered
to contact them offer to accommodate these features and
functions. Seamless integration of implants with the human
body as well as solutions to drug delivery problems through
neuroprotective barriers require technological precision at the
nanoscale.[12–14] The intrinsic properties of nanomaterials
enable the engineering of cellular interfaces[12,15–20] and
multiple challenges of long-term communication with live cells
make it essential if not inevitable that nanomaterials be used to
interface with cells.
The nexus of neurons and nanoscale materials can also be
examined from the perspective of a materials scientist. The large
class of currently available nanomaterials contains many
families of nanostructures, including nanoparticles (NPs),
nanowires (NWs), multi- and single wall carbon nanotubes
(CNTs), polymer coatings, silicon lithographic elements, and
nanodevices. All of these nanostructures have the potential to be
juxtaposed with living cells, offering great opportunities for
cellular interfacing. Significantly, recent applications of nano-
technology in other fields, such as electronics, optics, and
structural composites has provided a newfound wealth of
information about the electrical, optical, and mechanical
properties of nanomaterials. This rise in knowledge and
expertise has already started contributing toward a natural
transition of nanomaterials applications from electronics to
neural interfacing. As discussed below in Section 2.3, NEs
require a combination of a disparate variety of properties—a
combination that is becoming increasingly difficult to attain
with traditional materials. Practical design aspects of NEs also
bring about other potential biomedical applications of nanos-
tructures anticipated for neural tissues, such as neural guidance,
differentiation, and drug delivery. Optical and magnetic
properties of nanostructures open possibilities of using
nanocolloids for improved methods of monitoring excitation
in neurons. Overall, our primary focus in this review will be on
the use of nanomaterials for NEs and devices interfaced with







3972systemic functions of nanocolloids will also be discussed,
though only in relation to specific tasks related to neural tissues,
since much attention to optical and magnetic imaging with
nanocolloids has been already given.[21–29]
This work comes from a collaborative effort of scientists and
engineers from both the nanotechology and neuromedicine
sides of the aisle, united by common interests in neural
interfacing. The review has three purposes: (i) to review and
identify the challenges facing NE development and to establish a
framework of materials requirements for such devices; (ii) to
comprehensively review recent progress in the application of
nanotechnology toward neural interfacing; (iii) to suggest a
course for subsequent research and development efforts in this
dynamic area.2. Current Status of Neural Interface
2.1. An Overview of Traditional Neural Electrodes
The history of biomedical use of neural electrostimulation
tissues goes far back in time. To a large degree it accompanies the
process of discovery of electricity by mankind. Ancient Egyptians
(2500BC) used 400V electrical shock from electrical catfish as a
pain relief[30] and as a treatment for many ailments including
hemorrhoids. There are also speculative pieces of evidence that
electrical stimulation was also used in religious ceremonies as a
method to affect the spirit of life ka.[31] Ancient Greeks applied
electrical impulses from electric eels in foot baths helped pain
relief and enhanced blood circulation. In 47 AD, a physician
Scribonius Largus accidentally came into contact with an electric
torpedo fish (Black Torpedo Ray) and suddenly developed a cure
for gout, which later was accepted in general practice.[32] The first
scientific studies of stimulation of effect of electricity on animals
are often incorrectly attributed to Luigi Galvani[33,34] who
introduced a fairly vague concept of animal electricity after
experiments of electrical stimulation of frog legs published in
1791.[35,36] However, one of the Founding Fathers of the United
States of America, who also was a prolific inventor and scientist,
Benjamin Franklin, investigated the effect of the muscle
contraction that followed electrical shock as early as 1759.[37,38]
There are also indications that Peter Abildgaard, the founder of
Royal Danish Veterinary College, was also one of the first
scientists to demonstrate the contraction of muscles by electrical
stimulus.[31]
The next generation of NEs did not differ that much from the
1700s versions by design principle but differed significantly in
respect to their physical dimensions. The reduction in size of NEs
allowed Hodgkin and Huxley to study electrical signals from
individual neuronal fiber in 1939 and conceptually change this
field of knowledge: it led to extensive development of signal
transduction theory in neurons.[39] Not surprisingly, the next
pivotal step in NE development began with the new level of
dimensional control over these devices. Development of
micromachining resulted in introduction of a single metal wire
electrodes and early wire array electrodes,[40,41] which eventually
led to the revolution in NE technology and transition from the
laboratory to large number of patients. As such, after being 2009 WILEY-VCH Verlag Gmbapproved by the Food and Drug Administration (FDA) in 1985 for
adults and in 1990 for children, 70 000 cochlear prostheses were
implanted worldwide by 1999.[42] According to the FDA data from
2005, nearly 100 000 people worldwide have received cochlear
implants. In the end of 1960s and early 1970s, the research efforts
at Stanford University and the University of Michigan by Angell,
Starr, Wise, and later Najafi resulted in the first silicon-based NEs
manufactured by using lithographic and etching technolo-
gies.[43,44] Later in the 1990s, Normann and co-workers[45] from
the University of Utah applied methods of microscale sawing and
columnar etching to produce one-chip arrays of NEs for
long-term intracortical implantation. Considering this historical
timeline, one can project the next conceptual step in the
development of NEs will be associated with nanoscale processing
of materials.
Nowadays, diagnostic, therapeutic, and treatment strategies for
neural problems rely increasingly on electrical stimulation and
recording techniques. Besides cohlear implants, deep brain
stimulation (DBS)[46–49] is probably another good example of the
rapidly growing field of medical practice for NEs. Also, central
nervous system (CNS) implants has been developed to correct
motor disorders,[50] while implants in peripheral nervous system
are used or control pain, muscle contraction, and activity of
specific organs. CNS implants are also considered as a device to
translate willful brain processes into actions of external electronic
or mechanical systems.[51–53] Notwithstanding a certain degree of
controversy regarding their efficacy, safety, and ethical appro-
priateness underscoring the need for further studies and device
improvements, NEs have significantly improved the quality of life
for an increasing number of people suffering from neurological
disorders and injuries.[54,55a]
Since their discovery, penetrating electrodes (Fig. 1A–C and G)
and cuff electrodes (Fig. 1D–F) have been conceptualized and
reduced to practice to meet more specific needs. The penetrating
electrodes, such as the so-called Michigan electrode
(Fig. 1A–C)[10] or Utah electrode (Fig. 1G and H),[34] are used
for stimulation and recording of brain tissues, while the cuff
electrodes are implanted around peripheral nerves. Both
penetrating and cuff NEs (Fig. 1A and F) may have several
points of electrical interface with cells, allowing for the
simultaneous stimulation or recording of multiple areas. NEs
are sometimes considered as prototypes of brain-machine
interface. In general, the direct connection between brain and
a computer is certainly an interesting and motivating goal, which
is worth considering.[56] As a fairly remote possibility, such
bio-electronic devices may remove the information junction point
represented by the keyboard used to type this sentence. As a
closer target, direct information exchange technologies can
greatly help paralyzed individuals and amputees.[52] The use of
nanostructuredmaterials toward these technologies is expected to
be most essential and, most likely, inevitable. However, we would
like to emphasize that hyperbolization of this subject by some
scientists and science press overshadows many important health
problems that can be alleviated by the use of NEs as well as
technical issues.
Aside from establishing an electronic communication link
with neural tissue, there are other immediate and acute needs for
developing NEs related to devastating diseases. For example,







Figure 1. A) Brain stimulation electrode developed in Michigan, the so-called ‘‘Michigan
electrode’’; B) close-up of the implantable part in earlier models. The single recording site is
at the tip of the shank. Both images were reproduced with permission from [10]. Copyright 2005,
IEEE. C) Encapsulation of implanted model of Michigan electrode marked as S in the brain of a
rat: red stain is glial fibrillary acidic protein typical for astrocytes (GFAP), green stain OX-42
protein typical for microglia and macrophages, blue stain Hoechst 33342 dye with cell nuclei
specificity. Much smaller model marked as L has much lower concentration of astrocytes and
microglia around it. Reproduced with permission from [111]. Copyright 2007, Elsevier. D) Typical
cuff electrode. Reproduced with permission from [55b]. Copyright 2005, Blackwell. E) implanted
cuff electrode over sciatic nerve of a cat. Reproduced with permission from [112]. Copyright 2006,
IOP. F) schematics of the typical implantation of a cuff electrode around the vagus nerve (picture
is adapted from an original attributed to Cyberonics, Inc.); G) array electrode developed in the
University of Utah, the so-called ‘‘Utah electrodes’’; H) schematics of the potential next
generation prosthetic arm driven by recording and stimulation from Utah electrodes (both
from [34]). Both images were reproduced with permission from [34]. Copyright 2007, Nature
Publishing Group.proven to dramatically alleviate symptoms in patients of
Parkinson’s[50,57–59] and even Alzheimer’s diseases.[60] NEs have
also allowed patients of amyotrophic lateral sclerosis and paralysis
to regain their motor control and function.[9] Cuff
electrodes around peripheral nerves are used for treatment of
numerous disorders from loss of hearing, chronic pain and
Parkinson’s disease to depression and arrhythmia.[61–71] NEs also
offer the potential for restoring mobility of limbs and other parts
of the body in case of injury or paralysis (Fig. 1H).[72]
Despite general success and proven clinical relevance, for
instance with DBS and cochlear implants, there exist practical
and fundamental challenges related to the utilization of NEs.
While most chronically implanted electrodes appear to be well
tolerated initially, long-term electrode viability remains a
significant problem. Reduction of electrode size without
sacrificing the electrode’s ability to transfer charge to a cell is
critical for improving stimulation techniques. From the
biological side, much is still unknown regarding the response
of neural tissue to the long-term presence of implanted
electrodes. Significant strides toward more effective, smaller,Adv. Mater. 2009, 21, 3970–4004  2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinand safer electrodes hinge on improvements
of biocompatibility, charge transport, mechan-
ical compliance with the surrounding tissue,
chemical stability of the electrode materials,
the ability to influence neuronal growth, and
drug delivery capabilities.[46,47,49,72–75] Tech-
nologies geared toward elucidating the inter-
action pathways of neuronal networks are also
in the early stages of development and will
require new methods of imaging and signal
tracing.2.2. Brief Overview of Electrical Processes
During Electrostimulation and Recording
In order to better appreciate the problems and
to evaluate nanostructured materials from the
perspective of NEs, it is necessary to give a
brief overview of the actual electrical processes
taking place at the neuron/electrode interface.
The ability to interface with neural tissue is
anchored in the movement of electrical charge
between the electrode and the surrounding
tissue.[47,49,72,73,76] We need to point out that
we will give here fairly simple description of
the processes, which is sufficient to appreciate
the key challenges of the field related to design
of new materials but does not present the
process of neural stimulation in all complexity
of the events taking place. We omitted the
detailed information on extracellular current
flows, the mechanisms of neuron reactions to
an electric field or an injected current,
sequence of closing and opening of ion
channels, current and novel methods of
recording of neural potential including sub-
threshold signals, and only briefly discussedthe reaction of tissue as a whole to electrical stimulation. It was
done because there are excellent reviews written on these subject
and we encourage the reader to supplement the information
provided here with additional details when they are
required.[77–81]
The electrical processes taking place during stimulation and
recording are fairly identical, with the exception that the sequence
of charge movements is reversed and magnitude of currents in
the recording modality is smaller. For stimulation, charges are
delivered to the electrode and induce the shift in the membrane
potential of the neuron. For recording, the fluctuations of
membrane potential cause the current to go in and out from the
electrode. Having an effective interface is a prerequisite for both
stimulation and recording although the amount of charge
required for stimulation is orders of magnitude higher than
what is recorded. The optimal dimensions of the electrode which
are inherently tied to its electrical properties can also be quite
different for stimulating and recording.
For safe stimulation, the electrode must deliver appropriate







Figure 2. A) SEM image of IrO electrode, scale is 0.5mm. Reproduced with
permission from [82]. Copyright 2007, ECS. B) SEM image of Au electrode
with a layer of impedance-reducing porous TiN film, scale 0.75mm.
Adapted with permission from [33]. Copyright 2002, Annual Reviews.
3974reactions on the electrodes. Faradaic processes resulting from
reduction–oxidation (redox) electrochemical reaction between
species in solution and electrodes generally must be avoided
during cell stimulation except in the special case of some rare
materials such as Ir (see below).[82–85] Maximization of the
capacitive or non-Faradaic charge storage arising frommovement
of charged ions in the electrolyte toward or away from the
electrode is a critical consideration in successful NE design.[47,49]
Large electrode surface area accessible to ions can greatly increase
the capacitive component. Thematerial selection for the electrode
is, thus, a critical determinant for this process as the materials’
structure can significantly impact the surface area.
Electrical stimulation is typically carried out by a biphasic
rectangular signal with equal cathodic and anodic charge
distribution (net charge¼ 0). The charge per phase (in mCph1
or mCph1) and charge density (in mCcm2) are derived from
the integral over one phase of a waveform.[74] These two
parameters are commonly employed to determine the threshold
conditions for triggering injury during electrical stimulation, thus
stressing the importance of the stimulation current magnitude
and frequency, as well as the electrode size, for safe and efficient
stimulation. The charge injection limit is determined by the
amount of charge that can be injected without causing electrode
degradation or electrolysis of water. The size requirement for
electrodes typically requires the electrode to be small enough to
enable selective stimulation of a targeted population of neurons,
with an area typically 2000mm2.[86] Several materials have
already been identified as biocompatible, corrosion-resistive
candidates for electrical stimulation and implantation, including
noble metals such as Au, Ti, TiN, Pt, Rh, IrOx, stainless steel,
alloys of these metals, highly doped semiconductors such as
silicon, and conducting polymers. Two electrode materials are
used most commonly in practical medicine: Pt and iridium oxide
(IrOx). Pt is resistant to corrosion and has charge storage
capacities in the range of 300–350mC cm2. Platinum/iridium
(Pt/Ir) alloys have been explored to boost the mechanical
properties of the electrode without sacrificing its charge
capabilities. In the case of iridium oxide (IrOx), reversible redox
reactions
Ir2þ ! Ir4þþ2e and Ir2þ ! Ir3þþ1e (1)
occur at the electrode/media interface and significantly increase
the charge storage capacity of this material. The product of these
reactions, commonly denoted as IrOx, forms a thin film on the top
of the electrode in the vicinity of the cells (Fig. 2) and boosts the
charge injection to the range of 2–3mC cm2. Safe limits for
electrical stimulation of tissue vary depending on the target of
interest; a typical charge of 0.2–0.5mC is needed.2.3. Current Challenges of Neural Electrodes2.3.1. Reduction of Size
It is desired that NEs selectively excite or record from one neuron
at a time or even from one neurite at a time. Reaching these 2009 WILEY-VCH Verlag Gmbcapabilities will make possible not only fine-tuning of the curative
effect of established medical treatments with NE but also
fundamentally novel neuroprosthetic devices. Reduction of the
size of the electrode is also intrinsically related to the reduction of
injury to the tissue and scarring, which represents one of the
most important problems for NEs (see Section 2.3.3). Ir/IrOx
allows one to reduce the size of electrodes compared to Pt or Au
electrodes; but, nevertheless, the electrodes currently used in
neurology are substantially larger than single cells having
excitation/recording areas extending 70–150mm in all directions
from the electrode. This volume contains from dozens to
hundreds of cells. To a large degree, the difficulties with further
miniaturization are related to the fundamental limits of currently
used materials in respect to charge storage capacity and
impedance. Further reduction of electrode size requires not only
the development of new materials but also different methods of
excitation and recording using field effect transistors (FETs, see
Sections 5.6 and 5.7), for example, rather than simple metallic
spikes. In the case of FETs, however, the gap between the neuron
and the electrode has much greater effect on the electrode
performance than in traditional implants, such as Michigan
electrodes, thus requiring much better adherence of the
surrounding cells to the surface of the device. In turn this
requirement becomes more difficult to accomplish as the size of
electrode diminishes.
2.3.2. Problems Related to Mechanical Properties
Mechanical properties of NEs have been in the center of their
development for a long time. They were considered however
primarily from the stand point of having high enough strength
and stiffness to penetrate through pia arachnoid memberane on
the brain tissue,[87] and a drawback of some plastic electrodes was
considered to be difficulty with their insertion, so that the implant
site needs to be made by cutting the tissue.[88] Here we will
consider themechanical properties primarily from the standpoint
of long-term biocompatibility.
Many common NEs except some electrodes for DBS, Utah
electrodes, and some others are made by the deposition of a
conductive and high charge capacity metal layer onto a lower
performance substrate (Fig. 1). Even the formation of an IrOx
layer on metal electrode by electrochemical means or deposition
of an impedance-reducing TiN layer on Au by vacuum sputtering
results in a sharp interface between the materials (Fig. 2) which






www.advmat.dewhen one material becomes separated from the other. A simple
demonstration of the great importance of mechanical properties
for NEs is the fact that thin metal coatings can withstand only
limited number of flexural motions without cracking of the lower
performance substrates. This limitation is particularly significant
in the design of cuff electrodes. For currently used spike-like NEs,
strength and stiffness of the electrode shaft is essential for
implantation as well as for successful integration with tissue.
Mechanical properties of thematerial in contact with the cells also
have tremendous effect on their biological behavior.[89,90] These
examples highlight the need to focus attention on mechanical
properties of NEs, such as strength, stiffness, toughness, and
adhesion.
Delamination of the conductive interfacial layer has been
reported in many types of metal electrodes. Delamination results
in the deposition of inflammatory tissues and proteins onto the
electrode,[86,91] but even more damaging is the formation of a
microscale gap between the device and the surrounding neural
tissue. This gap causes significant reduction in the recording and
charge injection capabilities over time because a layer of
electrolytes slips between the conductive coating and the backing
of NE, causing multiple problems for electrical stimulation of the
cells.[92] Eventually delamination leads to complete failure of the
electrode.
2.3.3. Inflammatory Response of Neural Tissues
The goal of every implantation is to achieve a stable interface, as
characterized by minimal cellular change in the surrounding
tissue and sustained functioning of the implanted device.
However, the functionality of currently used NEs is limited
due to the biological response that results from electrode
implantation and their constant presence in the host tissue.[93–95]
This chronic inflammation takes the form of glial scarring
(Fig. 1C) which results in replacement of neuronal cells with glial
cells,[96,97] loss of electrode function due to encapsulation,[93] and
impediment to axonal re-growth.[98] Implantation of NEs usually
results in localized activation of resident immune cells,[99] such as
reactive astrocytes, taking shape as both an early and a sustained
response occurring over a long period of time.[94] In general,
microglia and astrocytes respond in short times after implanta-
tion. Immunohistochemical markers specific for these cells are
up-regulated during the first few days and may remain elevated
for months, but may subside over time depending on the type and
severity of the perturbation.[99–101]
Regarding the long-term (3–6months) inflammatory response,
various studies have reported astrocytic elements to surround and
grow on (i.e., encapsulate) electrodes implanted in the CNS. This
encapsulation causes an eventual increase in NE impedance, even
when systemic treatment with anti-inflammatory agents was
used.[93,102,103] Significantly, the encapsulation response seems to
be universal, occurring following implantation of a variety of
materials, including various metals, semiconductors, and poly-
mers.[94] It was hypothesized based on strong supporting evidence
that the failure of theNE devices over the long term is associated in
part with micromotions of the electrode in relation to the
surrounding neural tissue.[104–107] Micromotions originate with
natural movements of the head as well as with variations of blood
pressure. The resulting mechanical stresses on the cells at theAdv. Mater. 2009, 21, 3970–4004  2009 WILEY-VCH Verlag Gtissue electrode interface stimulate reactive astrocytes, which
perform immune functions in the CNS.[104,108–111] The large
mismatch between the mechanical properties of tissues
and electrodes is the main contributor of mechanical stress and
micromotions.[104,112] Damage to the neurovasculature caused
during implantation is also believed to contribute to the
inflammatory response[113,114] due, in part, to infiltrating immune
cells and other non-local cellular elements such as cyto-
kines.[115,116]
The second approach to inflammation primarily considers
physical dimensions of electrodes implanted in neural tissues.
The size of implanted objects seems to make considerable
difference in respect to activation of immune system and
inflammation (Fig. 1C). Macrophages in cell cultures do not
adhere to or spread on polymer fibers ranging in diameter from
2 to 12mm.[117] Decreased capsular thickness was observed when
polymer fibers with a diameter from 2.1 to 5.9mm were
implanted in the subcutis.[118] Physical dimensions of surface
features were found to affect mechanotrunsduction, adhesion,
and apoptosis.[102,119,120] The direct studies of the electrode size
on encapsulation also strongly suggest that inflammation
response is substantially reduced as the NEs become smaller
(Fig. 1C).[95,112] Technologically, manufacturing of smaller
electrodes is possible; however, the materials used for making
electrical pads on them (see Fig. 1B) do not provide sufficient
charge injection capacity, interface impedance, or actual
conductivity for successful reduction of NE dimensions. We
regard this approach as a complementary one to micromotions,
and eventually one would need a soft, highly conductive electrode
of small dimensions to mitigate encapsulation.
2.3.4. Necessity to Guide Neurons
Inflammation processes around NEs can lead to the replacement
of neurons in the vicinity of NEs with glial cells as described in the
previous section. Following the formation of the glial scar, the
number of neurons around the implanted electrode is greatly
reduced. Consequently, it would be desirable to guide the
neurons or their processes back to within a close vicinity of the NE
surface. Peripheral nerve interfaces designed to interface with
regenerating axons from an amputated nerve stump are another
example of a neural interfacing device that would benefit from the
development of materials capable of guiding neuronal
growth.[121]
The same challenges are also present in the field of peripheral
nerve repair. Long nerve gaps are currently bridged with
autografted segments of nerve, but this treatment has several
major drawbacks, including the need for a secondary surgery and
loss of donor site function. A potential alternative is to bridge
nerve gaps with guidance scaffolds containing materials able to
stimulate and direct axonal regeneration toward the distal stump
(see Section 4.1.3).
2.3.5. Poor Understanding of the Action Mechanism
There is a significant challenge to understand the mechanism of
NE functionalities for DBS and cuff electrodes. The body of
knowledge about the propagation of the signal in nerves during
the cuff electrode simulation contains many blank spots, but this







3976effective for the treatment of Parkinson’s disease, traumatic brain
injuries, paralysis, multiple sclerosis, depression, obsessive–
compulsive disorder and other malfunctions, DBS treatment was
found empirically. Only in single cases have fairy detailed studies
of DBS mechanisms were carried out. As such, reduction of
tremors in Parkinson’s disease is associated with the enhanced
release of adenosine.[122] However, in general, essential mechan-
isms of DBS are unknown.[122–125] A number of plausible
hypotheses explaining the clinical outcomes of DBS have been
offered. However, they are based on either inhibition or
stimulation of activity in the target brain structure.[126] In the
first case, neural output is regulated indirectly by the activation of
axon terminals thatmake synaptic connections with neurons near
the stimulating electrode. In the second case, synaptic inhibi-
tion[127] and depolarization blockade[128] may occur when
stimulation by NE alters the activation of voltage-gated currents,
which block neural output. For instance, reduction of activity of
neurons in orbitofrontal cortex was associated with the success in
treatment of obsessive–compulsive symptoms.[129]
This lack of understanding in how neuronal networks interact
with NE brings about the critical need of developing new model
systems for the study of signal propagation and associated cellular
processes taking place between neurons. Improvement of
imaging of different states of nervous tissue using both optical
and magnetic means will also be of great value here. These are
being actively pursued by many scientists working in nanotech-
nology. High contrast agents sensitive to the membrane potential
of neurons with short reaction times are much needed as well.
Semiconductor and magnetic NPs are being investigated for
these purposes.[130–136]3. Biocompatibility of Nanomaterials with Neural
Tissues
Applications of nanomaterials to the problems of the neural
interface must start with discussion of the potential concern of
biologists, physiologists, neurologists, and other scientists about
biocompatibility of nanostructures and neural tissue. Investiga-
tions of toxicity are partially instigated by the substantially
different properties that nanostructures exhibit relative to similar
bulk materials. For example, nanocolloids have a considerably
higher surface to volume ratio than bulk materials. It is precisely
this attribute which confers many of the positive features
linked to nanostructures being used for NE or drug delivery tasks,
but this attribute also significantly alters the biological pathways
in which nanostructures can participate and the kinetics of those
interactions.[137]
A good example of this phenomenon is the ability of
nanostructures to translocate across the brain–blood barrier
(BBB) through the olfactory bulb.[138] This pathway provides an
entry point to the CNS that seems unique to objects in the
nanosize regime. Once in the CNS, nanostructures canmigrate to
additional parts of the brain, traveling along axons and dendrites
and even crossing synapses.[137] In the case of neural prosthetic
interfaces, nanostructures would originate in the nervous system
as a component of a device or be intentionally introduced there;
however, it is likely that they could use many of the same
mechanisms to travel throughout the CNS. Thus, to fully 2009 WILEY-VCH Verlag Gmbunderstand potential nanostructure toxicity, it will be important to
examine the long-term stability of materials of NEs and/or other
nanoscale systems, such as NPs, NWs, single wall carbon
nanotubes (SWNTs), etc. that can be used for imaging purposes
in vivo, and to determine their ultimate distribution within the
CNS. These questions are not easily answered, and are dependent
on not only on the type of nanocolloids employed, but also their
surface modification, synthesis route, and size.
In this review, we shall focus mainly on the biocompatibility of
nanocolloids such as NPs and CNTs as the most controversial
ones. The other nanostructures made, for instance, from silicon
or some biological polymers present much less contention. Both
NPs[139–142] and CNTs[143–150] have shown toxic effects in general
cell culture when dispersed in liquids or gas. In depth study has
demonstrated that toxicity is linked to specific formulations or
material presentations. For example, SWNTs in solid composi-
tions or coatings appear to be exceptionally well tolerated by
neuronal tissues.[19,151–154] Creating non-toxic interfaces with
neural tissue will require a thorough understanding of these
relationships as well as development of new tools for the
assessment of neurotoxicity of the components.3.1. Toxicity of Nanoparticles
Optical properties of semiconductor NPs also known as quantum
dots open very interesting perspectives for new spectroscopic
tools to observe changes in membrane potential of neurons. This
is one of the key tasks in improvement of the understanding of
neural processes because the traditional voltage sensing dyes
based on redistribution of charged molecules between
phases, pH transitions, and spectral shifts in electrical fields
used now are either too slow or provide insufficient signal-
to-noise ratio (or both). Development of a new generation of
voltage sensitive membrane-resident labels is much needed, and
NPs can theoretically provide this opportunity due to high
polarizability of excitons. However, the problems related to their
cytotoxicity need to be taken into account.
There are numerous studies about cytotoxicity of NPs from
different materials and to different types of cells.[155–163] Overall,
the most predominant although not the only paradigm of NP
cytotoxicity is that they stimulate generation of reactive oxygen
species (ROS) and interfere with function of mitochondria. Here
we will focus mainly on interactions of NPs related to nervous
system and on semiconductor nanocolloids. Metal and metal
oxide NPs, such as Au, Ag, Fe3O4, Fe2O3 (see Section 4.2), and
SiO2, are generally much less toxic and controversial. Moreover,
some of them are already used in clinical practice. Toxicity of
organic NPs (see Section 4.1), such as liposomes, solid lipid NPs,
and nanocolloids from biodegradable polymers has been
discussed in literature extensively and should be reviewed
here.[164–169]
Several studies report toxicity of semiconductor NPs, such as
CdS, CdSe, or CdTe, to neural cells, with effects including
changes in cell morphology,[170] depressed metabolic activity,[170]
decreases in cell viability,[171] and increased lipid peroxidation.[172]
For example, PC12 neuroprogenitor cells exposed to cysteamine
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neuroblastoma cells experienced a decline in cell viability upon
short-term exposure to CdSe NPs.[171] However, neurons are not
the only, or even the most commonly, affected cell type in the
CNS.
Given that astrocytes have a key role in the brain’s response to
stress, they may provide the best indication of nanotoxicity in the
neural system. Astrocytes have two general phenotypes a resting/
quiescent type and a reactive type, in which a specific protein
GFAP is expressed in the cell membrane. Such cells are denoted
as GFAPþ astrocytes and are typically produced in response to
injury or a foreign body. Activation to this reactive form is a strong
indication of a toxic response. In a recent study, it was found that
NP uptake was enhanced in astrocytes relative to neurons, and
that GFAP expression was upregulated, although the length and
intensity was dependent on the type of NP investigated.[173] In
addition, another immune-like cell type, microglia, and in
particular those that act as brain phagocytes, were activated by NP
injections.[173] These results indicate that NP exposure can induce
an immune response in the CNS.
However, despite their clear potential for toxicity, several
reports describe the use of NPs with no ill effects. For example, no
difference in ion channel conduction for cells exposed to CdSe/
ZnS NPs in the nM regime was found.[139] A different study did
not reveal any evidence of toxicity in commercially available CdSe
NPs conjugated to nerve growth factor (NGF).[174] NGF-NPs
activated the expected tyrosine kinase A receptor, inducing
neurite outgrowth and extension; albeit at a somewhat lower rate
than free NGF.[174] These results underscore the fact that NP
toxicity is a complicated and controversial issue, with toxicity
being profoundly influenced by composition (core and ligands),
size, and localization.
3.1.1. Toxicity Attributed to Nanoparticle Composition
NPs are composed of materials (e.g., cadmium, lead, mercury,
sulfur, selenium, or tellurium) that can be toxic individually.
Notably, cadmium, a primary constituent of the most common
type of particles employed (e.g., CdSe), is a carcinogen, and has
been linked with cancers of the lung, prostate, and kidney.[175]
Carcinogenic effects are believed to result from interference with
DNA repair processes,[176] possibly by cadmium binding to repair
proteins. Cadmium also binds to metallothionein protein,
disrupting zinc metabolic pathways in the liver and kidney.
More specific to the CNS, cadmium is a known neurotoxin,
influencing lipid peroxidation.[177] Cadmium persists in biologi-
cal systems, meaning that toxic effects can occur long after the
initial exposure. However, the effects described here are for free
cadmium. In NP form, cadmium ions are complexed with other
materials, which may render them less toxic.
Similarly to other NPs, the most likely cause of quantum dot
toxicity is the formation of ROS resulting in the so-called oxidative
stress. ROS diminish cellular respiration, increase permeation of
the cell membrane, and damage the nucleus, leading to eventual
cell death.[141] For cells exposed to NPs, this loss of cell viability
can be attributed to apoptosis, and not necrosis, a finding
supported by observed upregulation of apoptosis-associated
proteins (e.g., selected caspases, JNK, Bax/Bcl-2).[171] In addition
to immediate effects on cell viability, NPs can cause DNAAdv. Mater. 2009, 21, 3970–4004  2009 WILEY-VCH Verlag Gfragmentation[171] and epigenetic changes.[178] In a detailed gene
analysis study, it was determined that gene expression was
relatively unaltered in the presence of NPs coated with silane and
poly(ethylene glycol) (PEG): 0.2% of genes tested displayed
differences.[179] However, the few genes that did display
differences included some involved in cellular stress responses.
Further, it was shown that NP exposure can produce epigenetic
changes, activating the p53 pathway.[178] Most initial studies have
been confined to evaluation of cell death, which while important,
may not reflect subtle and equally damaging consequences that
occur at lower, sub-lethal exposure levels. Only recently have
researchers employed techniques such as high throughput
screening to systematically identify these lower level
effects.[179,180]
3.1.2. Toxicity Attributed to Nanoparticle Core
It is widely believed that the primary culprits in production of
ROS are Cd2þ ions, most likely released as a result of
photooxidation of the particle core.[142] These ions are thought
to bind mitochondrial proteins, diminishing cellular respiration
and ultimately leading to cell death.[142] However, Cd2þ ions may
not be directly responsible for ROS-induced damage. One
observation that supports this theory is that cell viability does not
directly correlate with intracellular (IC) [Cd2þ], as one would
expect if Cd2þ ions are the sole cause of cytotoxic behavior.[181]
Additionally, when free radical scavenging chemicals (i.e.,
N-acetyl cysteine and vitamin E derivatives a-tocopherol or
Trolox) are added to cell culture medium, toxicity is reduced for
some, but not all, of the compounds tested.[170,171] It is instead
possible that toxicity results from ROS that are produced
indirectly, say by charge transfer to an intermediate molecule,[181]
a property which has allowed NPs to be used in photodynamic
therapy.[182] Regardless, it is clear that access to the particle core, is
a primary initiator of ROS events.
To minimize access to the core, it is possible to surround the
particle in a protective material. For example, layer-by-layer
assembled films of CdTe coated with collagen provide some but
not complete protection.[183] Marked reduction of the toxicity
effect was observed even for fairly thin protein coatings, which
was attributed to the reduction of the contact of cells with the NP
core and exposure of cells to Cd2þ. Similar observations were also
documented for ZnS and bovine serum albumin (BSA) coatings,
which dramatically improved cell viability.[142] IMR-32 human
neuroblastoma cells exposed to CdSe NPs displayed a 50–60%
decrease in cell viability (MTT assay) over cells exposed to ZnS
capped NPs.[171] In general, surface coatings that have shown
great efficacy in reducing NP toxicity include ZnS
caps,[139,142,171,181] BSA,[142,170,184] and the combination of
silane/silica and phosphonate.[139,179]
3.1.3. Toxicity Attributed to Nanoparticle Surface Functionalization
In addition to the particle core, the type of ligand on the NP
surface can affect NP toxicity. In fact, Hoshino et al.[184,185] asserts
that NP surface ligands may have a greater effect on cytotoxicity
than the NPs themselves. Ligands identified as cytotoxic include
trioctyl phosphene oxide (TOPO),[184] the classic organic
synthesis ligand, mercaptoundecanoic acid,[184,186] and mercap-







3978acid).[139] In most cases, cytotoxicity was manifested as decreased
cell proliferation or DNA damage. Although ligands undoubtedly
contribute to toxicity, it is doubtful that they are the only, or even
primary, cause. For example, in a controlled study of CdSe and
CdSe/ZnS NPs with similar surface ligands, the unprotected
CdSe NPs were much more toxic than the CdSe/ZnS NPs.[139]
This difference was attributed to increased access to the NP core.
Similarly, in the same study, when compared to molecules,
toxicity of Cd2þ ions played a greater role than that of the ligand
(i.e., mercaptopropionic acid).[139] Nonetheless, these studies
indicate that ligand selection and removal of synthesis
contaminants (i.e., TOPO) are extremely important in developing
biocompatible particles.
3.1.4. Toxicity Attributed to Nanoparticle Size
Composition is just one facet of NP toxicity. Particle size also
influences cell behavior, with smaller particles generally found to
bemore toxic than larger particles.[170,186] Detailed analysis seems
to indicate that this size dependence is a direct result of the
surface to volume ratio of small particles.[139] As particle size
decreases, the surface to volume ratio increases significantly, and
more surface Cd2þ atoms are available for reaction and
subsequent cell poisoning. Alternatively, it is also possible that
smaller particles are processed through alternate transport
pathways. For example, in one study, smaller green NPs, which
were localized in the nuclear compartment, were much more
toxic to neural cells than larger red NPs excluded from that
compartment[170] (Fig. 3). It is hypothesized that access to the
nucleus, and hence DNA, may accelerate toxic responses. If so, it
will be critical to ensure accurate targeting and core protection of
particles for drug delivery and gene therapy studies.
An additional source of toxicity dependence on NP size can
originate from the dependence of redox potential and semicon-
ductor band gap on their diameter. Considering the possibility that
ROS can be generated on the NP surface, redox properties can
exhibit an exceptionally strong effect on the amount of free radicals
produced. Alternatively, photoexcitation of semiconductor NPs
can lead to independent generation of free radicals from adsorbed
photons, which is obviously affected by quantum size effect in the
semiconductor core. The enhancement of NPs toxicity upon
illumination had been experimentally documented.[142]Figure 3. Microglia exposed to A) red CdTe NPs 6–8 nm in diameter and
B) green CdTe NPs 3–4 nm in diameter at 50 nM after 24 h of exposure.
C) Exposure to green NPs produces greater reductions in cell viability than
larger red NPs (64.9% vs. 87.6%), which are excluded from the nucleus.
(Courtesy of Dr. Dusica Maysinger, McGill University, Montreal, Canada).
 2009 WILEY-VCH Verlag Gmb3.2. Toxicity of Carbon Nanotubes
In general, the response of neural tissues to CNTs has been
positive.[154,187–194] The biocompatibility of CNT at the cellular
level has been verified by several studies,[195,196] but the
widespread adoption of CNT-based technologies for biological
and medical applications requires a cautious approach regarding
the potential toxicity of CNTs to the environment and human
health. Initial studies have revealed mixed results with respect to
the toxicity of CNT.[143,144,147,150,197–199] In regards to neural
applications, CNTs have been studied as possible substrates for
neuronal cell adhesion[200–202] and as thin films to enhance/
support neural excitation.[19,152,203,204] Toxicity has not generally
been observed for CNTmats, coatings, composites, etc., which do
not produce freely floating nanotubes (NTs).[19,151–154] However,
we still need to be mindful about toxicity of the dispersions
addressed in this part of the review because of potential
decomposition of the CNT composites used to manufacture
NE electrodes (see Section 5.6).
As with NPs, CNT toxicity appears to be a function of many
factors, including composition, surface functionalization, and
size. A clear understanding of these features will be necessary to
design biocompatible biomaterials for neural applications.
Dispersion of CNTs have been linked to toxicity in the brain,[138]
lung,[144,145] and skin.[143] The nervous system, in particular, has
long been a concern for carbonaceous nanomaterial toxicity. For
example, an early nanomaterial toxicology study identified that
C60 fullerenes molecules (see Section 4.1.2), which have
structural similarities with CNTs, increase lipid peroxidation in
the brain.[138] Although in vivo studies with CNTs have been few,
exposure has been associated with aneurysms, particularly in the
cerebellum, which may indicate degradation of the blood-brain
barrier.[205] In culture, neurons[206] and astrocytes[18] grown on
some CNT surfaces display reduced cell viability and adhesion,
when compared to standard growth surfaces. However, one needs
to be mindful of possible interference from the particles of
catalyst and other admixtures which can account for a large part of
toxicity observed in these studies. The presence of small amounts
of soluble toxic components should also be considered. In some
cases, such reduced viability can continue even after removal
from the CNT-coated substrate.[206] In this particular study, cells
did not evidence the same effects to conditioned medium
incubated with CNTs, implying that soluble toxic factors did not
account for reduced viability. Taken together these data suggest
that CNTs may induce epigenetic changes that continue to exert
effect long after CNTs are physically removed. This possibility is
especially troubling because CNTs are extremely resistant to
biodegradability,[207] and may persist in the body indefinitely.
Apart from viability effects, CNT films have been shown to
alter neurite branching, length and density, and the number of
growth cones (Fig. 4).[18,202,206] The exact mechanism behind
these changes is unclear. CNTsurface charge or polarity may exert
an influence,[206] possibly by influencingmetabolic processes. For
example, soluble CNTs can decrease the ability of neurons to
transport Ca2þ ions in response to membrane depolarization,[201]
which has been linked to extension of fewer but longer neurites
with a reduction in neurite branching. CNTs films have also been
shown to increase the frequency of synaptic activity and neuronal







Figure 4. A,B) Examples of two different neurites (green) extending from
neuron cell bodies align in the direction of CNT orientation (yellow arrow).
Scale bar¼ 20mm. (Figure courtesy of Dr. Thomas Webster, Brown Uni-
versity, Providence, RI).
Figure 5. TEM of HeLa cells exposed to ammonium functionalized
MWCNTs. CNTs successfully traverse the cell membrane, producing gene
transfection. (Courtesy of Prof. M. Prato, University of Trieste, Trieste, Italy;
adapted from [216].)for current transfer between adjacent cells. While this is not
directly a toxic response and is potentially advantageous for
neural prosthesis development, CNT-induced increases in
neuronal activity should be studied in more detail to preclude
the unlikely possibility of atypical neuronal responses. It should
be noted that neuronal resting potential and membrane time
constant, as well as action potential features, widely accepted
indicators of cultured neurons health, were not affected by pure
CNT substrates.[152,208]
3.2.1. Toxicity Attributed to Carbon Nanotube Composition
Similar to NPs, CNT toxicity is linked, in some measure, to
composition. All CNTs are composed primarily of carbon.
However, there are many different types of CNTs, including
SWNTs and multiwalled carbon nanotubes (MWNTs), each of
which can have different sizes and surface properties. Although
they structurally resemble graphite, CNTs have substantially
different electrical properties,[209] and therefore may behave
differently in the bulk than in the nanophase.[144] It is notable,
however, that graphite produces toxic responses, particularly in
the lung.[144] The lung is a specific concern for CNTs because they
are manufactured through processes by which they may easily
enter the air.[207] This is in contrast to NPs, which are synthesized
primarily through liquid routes. Most studies of CNT toxicity
examine effects on the lung or alveolar cells, with the typical
response being the formation of granulomas.[144,145,210] It is
important to point out that lung toxicity results at least in part
from mechanical blockage,[145] as opposed to inherent toxicity,
and thereforemuch of this datamay not readily translate to neural
systems.
A likely cause of toxicity, as with NPs, is the formation of
ROS.[143,149,211] ROS are probably created by CNTphotoexcitation,
which can generate free electrons.[137] ROS production appears to
be dose dependent,[210] most likely proceeds through a
Fenton-type reaction (i.e., catalyzed decomposition of H2O2
yielding OH radicals),[143] and may be related to iron catalyst
contamination. It is also possible that CNTs interfere with ROS
scavenging pathways (e.g., glutathione) rather than directly
producing ROS.[210] Observed ROS-related effects include
decreased cell viability through both apoptotic[148,159,210,212] and
necrotic pathways.[159] Specific mechanisms of response appear
to vary by dose.[159] In contrast to NP studies, evidence forAdv. Mater. 2009, 21, 3970–4004  2009 WILEY-VCH Verlag Gmitochondrial effects is conflicting.[210,211] CNTs bind the
formazan product produced in the classic MTT assay to assess
mitochondrial activity,[211] skewing results from papers that
assess fitness using only this mechanism and possibly
contributing to the confusion. Other tests have shown that
CNT exposure disrupts mitochondrial membrane poten-
tial,[211,213] although it is not clear if this results from ROS
production or penetration of themitochondrial membrane.[213] In
contrast to NPs, another substantial cause of unmodified CNT
toxicity may be their hydrophobicity. Whereas low concentration
of modified CNTs have been shown to successfully traverse the
cell membrane without cytotoxicity (Fig. 5), unmodified hydro-
phobic CNTs may insert themselves between the hydrophobic
lipids of the cell membrane,[213–216] resulting in disruption.
Internalized CNTs can also provide a physical barrier, disrupting
cytoskeletal proteins and organelle placement,[211,213] as well as
external mass transfer.[217] This action has been linked to
up-regulation of apoptotic proteins[148] and reduced expression of
many common cell adhesion proteins,[218] which may account for
CNT influence on neurite branching.[201] It is believed that these
processes are an attempt to encapsulate the CNTs, by surround-
ing them with detached apoptotic cells.[217] It is possible that
CNTs evoke these responses because of their size similarity to
viruses, and up-regulation of several proteins associated with
anti-viral response have been observed in response to CNT
exposure.[159] Hydrophobicity can be altered through an oxidation
process (acid treatment and/or plasma etch) to produce CNTs that
are COOH-terminated. Unfortunately, some oxidized CNTs have
been shown to be more toxic than their untreated counter-
parts.[199,212,217]
Another complicating factor is that CNTs are frequently
contaminated by trace amounts of the nickel or iron synthesis
catalyst.[198,207,218] These contaminants may be responsible for a
substantial portion of ROS production.[211] For example, SWNTs







3980production of OH radicals in activated macrophages, which can
be converted into H2O2, inducing oxidative stress.
[198] Acid
treatment can be used to remove catalyst contamination, and
significantly reduces toxic effects[198,217] as compared to the same
pristine material.
3.2.2. Toxicity Attributed to Surface Functionalization of Carbon
Nanotubes
Another influence in CNT toxicity is surface functionalization,
both type and degree. Charge, in particular, has been shown to
alter neurite extension, density, and length. For example, cells
exposed to more positively charged surfaces display more neurite
branching[200,202] and growth cones.[200] Polarity also appears to
play a role, although to a lesser degree[206] with polar surfaces
inducing higher neurite densities than non-polar surfaces[151,203]
These results are similar to those for other materials.[219,220] The
number of functionalization units also influences toxicity, with
increasing units decreasing toxicity.[150] It is hypothesized that
improved functionalization protects the NTsurface, reducing the
likelihood of photooxidation. However, it is also possible that this
toxicity results from other factors, including an increased
propensity to aggregation (see below).
3.2.3. Toxicity Attributed to Carbon Nanotube Dimensions
Size and shape may also play a role in CNT toxicity. From studies
in the lung, it has been established that the general chain of
toxicity follows the trend SWNTs>MWNTs>C60 (fullerenes)
when compared on amass basis.[221] This result has been difficult
to justify based on compositional differences alone, but may be
explained by a theory that, in contrast to NPs, materials with the
smallest surface area appear to be the most toxic.[218] Other
researchers; however, suggest a length dependence in toxicity
response. For example, studies examining MWNTs of different
lengths (but similar surface areas) found that longer CNTs were
more likely to provoke an inflammatory response and were less
likely to be engulfed by macrophages.[147] The exact mechanism
of these responses is unclear, but it has been suggested that small
hydrophobic particles may resemble viruses, inducing an
immune response.[159,218] The similarity of CNT size and shape
to viruses may influence the toxicity response evoked.
Apart from dimensionality, aggregation state has been shown
to have a strong impact on toxicity. Some researchers have found
that well dispersed bundles of CNTs are much less toxic than
aggregates, which may be as large as micron size.[214,222]
Aggregates appear to loosely bind cells, perhaps through their
extracellular proteins.[223] These aggregates may influence the
ability of nutrients and wastes to traverse the cell membrane.[217]
Alternatively, it has been suggested that aggregated CNTs exhibit
reduced surface areas that render them less toxic than more
well-dispersed materials.[218] However, others have shown that
the effect of aggregates is important, but not entirely responsible
for toxic effects.[223] For example, when SWNT-containing cell
culture medium was filtered to remove large aggregates
(>0.22mm), the filtered medium produced toxic responses only
slightly lower than that of unfiltered medium.[223] Upon further
examination of the filtered medium content, it was determined
that the medium predominately contained small SWNT bundles
(<5 nm) and graphite-like particles, which probably compro- 2009 WILEY-VCH Verlag Gmbmised 1% of the initial SWNTs by volume. The particles were
surrounded by amorphousmaterials, probably adsorbed proteins,
suggesting that one possible mechanism of in vitro toxicity is the
removal of serum proteins from culture medium. Because acid
and oxidative treatments that are used to remove catalyst
impurities can greatly enhance NT aggregation, it will be critical
to understand the role of aggregation in CNT toxicity.
3.3. General Conclusions about Cytotoxicity
Overall, the set of conclusions that can be reached from the entire
Section 3 are the following. (i) The largest component of
nanomaterial cytotoxicity is composition. (ii) Apart of some
dependence of toxic effects on size and aggregation state,
nanomaterials did not demonstrate fundamentally new mechan-
isms of cytotoxicity which would be specific to nanoscale. This
does not mean that they are impossible, but for the materials of
interest they are not engaged. (iii) The most significant concerns
are raised about semiconductor NPs containing Cd2þ. This can be
extended to other particles from heavy metals. So, these materials
should be avoided for the use in long-term devices, but can still be
applied for imaging in animals and ex vivo to establish, for
instance, a neuron firing sequence. (iv) Traditional materials used
in the design of NE and other implantable devices are not
expected to show drastically different mechanisms and/or levels
of toxicity after acquiring nanoscale features.4. Nanocolloids and Neuronal Tissues
This part of the review describes the applications of different
nanostructures in dispersed state, i.e., nanocolloids, for the
purpose of aiding the neural interface. They typically perform
the tasks of drug delivery or a contrast agent in imaging, which
have immense importance for practical neurology. Drugs can be
used to modulate inflammatory response, deliver factors
supportive of neural health and neurite outgrowth, and even to
introduce genetic material for targeted gene therapy. Temporal
and spatial control over the delivery of drugs and biological factors
is one of the key aspects of materials design for this function to
ensure safety and efficacy of NE and neural tissues in general.
Nanoscale particles, structures, and coatings offer the fine control
necessary to achieve this degree of selective targeting over
controllable timescales.
The same arguments are applicable to the description of
advantages of nanocolloids for imaging. Visualization of brain
activity and damaged areas of CNS represent continuous
challenges despite very significant progress made in recent
years. NPs have the ability to penetrate the BBB and accumulate
in certain areas of brain. Targeting of contrast agents still needs to
be improved greatly.
Besides serving as contrast agents, nanocolloids can theore-
tically serve as NEs as well. Although it would not be impossible to
imagine a self-organized system of NPs or similar species, such
as NWs or NTs, that form a conductive electrode-like network in a
specific area of the nervous system, the challenges of delivering
sufficient power to such a network and lack of a clear delivery
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scientific interest and importance to keep such systems in mind
rather than to dismiss them as an absolute impossibility.W
4.1. Organic Nanocolloids
In general, controlled delivery of drugs and biological agents can
be mediated by many different classes of NPs. In this section, we
will consider only those made from organic materials, such as
polymer-based NPs,[224] liposomes,[225–227] etc., while inorganic
NPs are reviewed in Section 4.2.
4.1.1. Drug Delivery with Organic Nanoparticles
NPs have the potential to cross the BBB[228,229] and can be
conjugated with ligands to enable targeting of specific cell types.
Liposomes for example, are nanoscale spheres composed of a
lipid bilayer surface that can encapsulate or incorporate drugs and
biological agents for delivery as exemplified in Figure 6 by
liposomes loaded with an iodine CT contrast agent for imaging.
Incorporation of polyethylene glycol on liposome surfaces
extends their circulation time in the bloodstream,[230] and
conjugation of various ligands enables selective targeting of
drugs to specific cell types.[225–227]
Biodegradable polymer NPs such as poly(lactic-co-glycolic acid)
(PLGA) can be used to achieve a tailored release profile of
encapsulated drugs over timescales of days up to months. NP
mediated drug release can additionally be localized by surface
binding of bioactive ligands,[231] incorporation of NPs within
hydrogels,[224] and a variety of other techniques.[18] The resulting
spatiotemporally controlled release allows for extended modifica-
tion of neural tissue in the vicinity of implanted devices. As an
example, localized delivery of anti-inflammatory agents to the
NE-tissue interface has been achieved by coating neural probes
with NP containing gels.[224]
NP-mediated gene delivery is another application with future
potential for influencing the behavior of neural tissue around anFigure 6. TEM image of loaded liposomes. (Courtesy of the group of R.
Bellamkonda, Georgia Institute of Technology, Atlanta, USA).
Adv. Mater. 2009, 21, 3970–4004  2009 WILEY-VCH Verlag Gimplanted device. Gene therapy offers the potential to modulate
neural growth and regeneration,[232] tissue response,[233] and
otherwise influence neural tissue behavior in a manner favorable
to establishing a neural interface. The use of viral vectors is
currently the most efficient and stable technique for genetic
transfer into targeted cells.[232,234,235] However, drawbacks
including safety concerns and undesired side effects associated
with the use of viral vectors have spurred research in the area of
NP-mediated gene transfer.[236] The use of liposomes[233,237] or
biodegradable polymers[238] conjugated with ligands again offers
cell targeting and temporal control of gene delivery.
Polysorbate 80 coated NPs are another example of potential
drug carriers across the BBB. These NPs are most likely absorbed
via endocytosis by the endothelial cells lining brain capillaries.
Polysorbate 80 causes the adsorption of apolipoprotein E from the
blood plasma onto the NP surface, creating particles whichmimic
low density lipoprotein (LDL) particles that interact with LDL
receptors, leading to their uptake by endothelial cells. Drug can
then be released in the CNS.[13,228,239,240] Imaging studies of these
NPs using analytical electron microscopy (AEM) with copper
chlorophyll as the contrast agent have confirmed that they do
indeed cross the BBB and accumulate in the brain.[241]
Another potential use of polymeric NPs is the treatment of
Alzheimer’s disease by metal chelator–NP complexes. The
abnormally high levels of redox-active metals in affected areas
of the brain in Alzheimer’s patients are difficult to treat with
metal chelators because they do not cross the BBB. However,
chelator–NP complexes may be a promising approach. They were
incubated with human plasma to adsorb apolipoproteins E and
A-I, facilitating transport across the BBB.[242] Cationic albumin
conjugated NPs being developed for gene delivery to the CNS
have also been shown to cross the BBB quickly and effectively
following systemic intravenous administration.[174,243] The
cytotoxic products of genes such as the proapoptotic Apo2 li-
gand/tumor necrosis factor-related apoptosis-inducing ligand
(Apo2L/TRAIL) may potentially be used to treat malignant
tumors by inducing targeted apoptosis (programmed cell death)
of cancerous cells. However, their delivery to the CNS is
hampered because conventional viral vectors cannot cross the
BBB, in addition to other safety considerations associated with
viral gene delivery vectors. If the safety and biocompatibility of
cationic albumin conjugated NPs can be established, this system
may prove to be a feasible non-viral gene delivery vector for
primary CNS tumors. Initial experiments using this system have
induced apoptosis in vivo and delayed tumor growth.[244]
4.1.2. Fullerene Derivatives
Fullerenes are being investigated as drugs and for small molecule
delivery tasks. This and othermethods used for their modification
make them much closer to organic NPs in terms of applications
in neurobiology than to their close relatives, i.e., CNTs, which are
utilized mostly for electrode manufacturing (see Section 5.6).
Fullerenes can be functionalized to be biologically compatible
while remaining resistant to metabolic degradation, which would
cause the release of toxic metal ions into biological tissues. One
application of water-soluble metallo-fullerene derivatives is their
use as magnetic resonance imaging contrast and therapeutic







3982(see Section 4.2). Such systems have been used to image rat
glioma cells in the brain,[247] a very aggressive neural glial
neoplasm associated with high morbidity and mortality. By
functionalizing the surface of the fullerenes, it was possible to
target the desired cell population and image at a concentration
that was an order of magnitude lower than required by routinely
used commercial contrast agents.[247]
Another potential application of fullerenes is neuroprotection,
the pharmacological rescue of neurons before they die following
disease or injury. This is a special property not ordinarily found in
other organic or inorganic NPs. Following injury of neural tissue
of brain or spinal cord, which can be exemplified by a trauma or a
surgery related to implantation of an NE, the primary mechanical
damage quickly initiates a complex chain of biochemical
reactions which lead to the so-called ‘‘secondary injury’’ that
includes biochemical processes such as free radical damage
involving ROS and excitotoxicity produced by the spillage of
neurotransmitters and excitatory ions. The effects of secondary
injury damage can extend far beyond the locus of the primary
mechanical injury, and result in the death of neurons relatively far
away. Immediately adjacent to the region of cell death produced
by the primary injury is a region referred to as the ischemic
penumbra, an area where effected neurons can be rescued from
cell death if pharmacological intervention is achieved quickly and
efficiently. Clinically, neuroprotection is important because the
rescue of even a small percentage of neurons can result in
significant clinical recovery. Hydroxyl functionalized fullerenols
have been shown to possess anti-oxidant and free radical
scavenger properties which are neuroprotective. These corre-
sponding fullerenes have been shown to result in significant
cellular rescue in animal CNS injury models{LL, 2001
#551;Dugan, 1997 #550;Dugan, 1996 #553;Jin, 2000 #562}. Free
radical injury is a major contributor to the disease process of
ischemic, traumatic, and degenerative disorders in the CNS, and
is a major component of secondary injury mechanisms.[248–251]
ROS including superoxide (O2.), hydroxyl (.OH), peroxynitrite
(ONOO), and peroxide (H2O2) can result in DNA fragmenta-
tion, peroxidation of cell membrane lipids, decreased mitochon-
drial energy production, and transporter protein inactivation.
Fullerenols have been shown to reduce and limit glutamate,
NMDA, AMPA, and kainite induced excitotoxic and apoptotic cell
death.[252–254] Although still an area of active research, the
mechanism of fullerenol-mediated neuroprotection is the result
of, at least in part, their ability to inhibit glutamate channels, since
GABA(A) or taurine receptors in neurons were not affected by
the fullerene derivatives. Fullerenols also appear to lower
glutamate induced increases in IC calcium concentrations, a
prominent mechanism of neuronal excitotoxicity.
4.1.3. Self-organized Scaffolds for Neuronal Guidance
The replacement of neurons around NE with reactive astrocytes
and glial cells can be combated by stimulation of neuronal growth
toward NEs. Along with other means described above, this can be
accomplished by using a specifically designed cellular environ-
ment, i.e., scaffolds. Bioactive and biocompatible peptide-based
self-assembling nanofibers that form self-supporting scaffold
materials are being developed for neural regeneration applica-
tions.[255–257] These types of systems are attractive because they 2009 WILEY-VCH Verlag Gmbcan mimic aspects of both the mechanical and biochemical
properties of the extracellular matrix. In doing so, they can signal
and induce very specific responses in neurons (e.g., chemotaxis
axon growth,[258] proliferation of neural progenitor cells, etc.). For
example, ionic self-complementary peptides assemble because of
the alternating positive and negative L-amino acids, which form
highly hydrated scaffolds at physiological conditions.[259–263]
These nanofibers signal neurons at molecular scales while in a
fully biocompatible system because the L-amino acids can be
broken down and metabolized. It is also free of chemical and
biological contaminants such as collagens, which are normally
present in animal-derived biomaterials, and is immunologically
inert. One study showed robust adhesion of PC-12 cells, a
neuronal derived cell line, and functional synapse formation in
rat primary hippocampal neurons with a arginine, alanine,
aspartate, and alanine (RADA)16-I scaffold.[260] Another study
using thismaterial facilitated the functional regeneration of axons
in a hamster model of severed optic nerve that resulted in partial
functional visual recovery.[259]
In another system, peptide amphiphile molecules were
developed to self-assemble under physiological conditions into
networks of nanofiber scaffolds.[255,256,264] The nanofiber surface
consisted of hydrophilic head groups of the peptide amphiphile
molecules that had aligned to form elongated micelles expressing
specific bioactive peptide sequences. In particular, the neuronal
specific extracellular matrix laminin-derived sequence isolucine-
lysine–valine–alanine–valine (IKVAV)[257] was used to promote
the outgrowth and elongation of neurites, the processes extended
by growing neurons. In water, the peptide amphiphile molecules
energetically prefer to be in solution, while in the presence of
cations, such as conditions found in physiological environments,
self-assembly is triggered and the molecules form nanofiber
scaffolds that trap the water molecules that surround them,
macroscopically forming a weak self supporting gel.[258] Because
of the conditions under which self assembly occurs, mixing
peptide amphiphile solutions with suspensions of neural
progenitor cells or neural retinal cells in culture media resulted
in their encapsulation in the three dimensional gels. Functional
cell signaling was induced because of the structure of the
nanofibers, and the measured response of the signaling was
confirmed using different assays. The end result was selective
and robust neuronal differentiation of the progenitor cells, with
minimal astrocytic differentiation.[257]4.2. Inorganic Nanocolloids
Another major class of nanomaterials being used for neu-
roscience applications are inorganic NPs, which form a diverse
family of materials capable of being functionalized including
silica NPs,[232] semiconductor, metallic and magnetic NPs.[265]
Overall, inorganic NPs in conjunction with neuron tissues are
used predominantly for the same tasks as organic cousins with a
difference that drug delivery is a less prominent functionality,
while imaging tasks are more predominant. Additionally there
are specific properties of inorganic NPs which are not
encountered in any other NP, which make possible unique






www.advmat.deSuper paramagnetic iron oxide NPs which are also often
abbreviated as super paramagnetic iron oxide nanoparticles
(SPIONs), have been used in magnetic resonance imaging to
detect neurodegenerative lesions with high sensitivity and
efficacy. They are typically made from oxides of iron and
manganese,[268] but Co/Pt or Au/Fe alloys[269] can also be
considered. For neural applications, the presence of Co is
undesirable because of neurotoxicity. Magnetic NPs are able to
cross the blood brain barrier by active transport mechan-
isms[228,268,270] or via the olfactory bulb.[271] Polyvinyl-alcohol
(PVA) and dextran coated magnetic NPs were investigated for
uptake using brain capillary endothelial cells, microglia (the
immune cells of the CNS), and three-dimensional cellular
aggregates.[272] These NPs did not induce the production of the
inflammatory mediators, at least in their simple test systems.
Amino PVA-SPIONs were taken up by isolated brain-derived
endothelial and microglial cells with no inflammatory activa-
tion. One potential exciting and unique application of these
NPs is targeted CNS drug delivery simultaneously combined
with magnetic resonance imaging detection.[272] Magnetic
dispersions capable of strong luminescence emission were
also made for better spatial resolution with magnetic
fields.[273,274]
In terms of the neural interface, magnetic NPs are particularly
attractive for treatment and imaging of brain cancer.[275–279] In
treatment modalities, the particles are used as a source of heat in
AC magnetic fields, which raises the temperature of cancer cells
and kills them (i.e., hyperthermia).[267,275] Alternatively, they can
be used for delivery of medical agents and targeted by external
magnetic fields.[280] Preliminary studies on the distribution of
magnetic NPs in animals have also been done and successfully
indicate crossing of the BBB.[14,281,282]
A class of NPs that is emerging as an important research tool is
semiconductor NPs (see Section 3.1). The optical properties of
quantum dots result in very specific and narrow excitation spectra
induced by rather broad absorption spectra, especially toward the
UV range. They are generally composed of a CdSe or CdTe core.
As described in Section 3.1, they are often coated with a zinc
sulfide cap to enhance their luminescence and to make them
more biocompatible. By functionalizing their surface, they can be
used to tag molecules of interest in biological systems.[283–288]
Quantum dots have been used to label and track both neurons
and glial cells, the two major classes of cells in the CNS.[173,289]
One unique and technically very difficult application that this
technology is particularly well suited for is the probing of
individual receptors, such as neurotransmitter receptors.[290] In
neuronal chemical synapses, the space between the pre- and
postsynaptic neurons where the presynpatic cell signals a
postsynaptic one via neurotransmitter release, is only about
20 nm[291] and molecularly very diverse and heterogeneous,
making it an extremely difficult structure to study. The size,
functionalization, and optical properties of quantum dots make
them a potentially invaluable tool for this application.5. Surface Nanostructures and Neural Tissues
Continuing the discussion about the interactions of nanomater-
ials and neural tissues following the previous sections onAdv. Mater. 2009, 21, 3970–4004  2009 WILEY-VCH Verlag Gbiocompatibility and nanoscale colloids, we can move on to the
topic of how nanostructured systems can eliminate or mitigate
the challenges of neural interface outlined in Section 2.3. Indeed,
there is a significant success in all of the directions mentioned
from improving the charge storage capacity, to single neuron
addressing, to mitigation of inflammation including the
techniques involving nanoscale colloids. In this section, we will
describe approaches based on nanostructured surfaces, which are
probably more direct and diverse compared to what we have seen
so far in case of NPs and similar dispersions.5.1. Basic Electrode Design
Cell organelles and structures responsible for the interface with
NE span the range from nanometers tomicrometers in size.[18] As
was mentioned already, biological structures such as growth cone
filopodia and extracellular matrix proteins lie within the
nanometer range,[292,293] as do many other relevant structures
in the cellular environment. For example, basement membranes
that provide the surrounding structure for most cells are
composed of a dense meshwork of three-dimensional topogra-
phy, featuring pores and fibers with dimensions ranging from
tens to hundreds of nanometers.[294] Therefore it seems logical to
us that NEs should have scale of at least some features in the same
nanometer range.
We will confine the discussion here predominantly to the
nanoscale features of electrodes which have a solid interface with
cells although some radical departure from the traditional
electron-transporting electrodes should also be noted. One
example of this type of a non-conventional electrode is the
microfluidic-based stimulating electrodes,[295–302] which can
arrange the delivery of chemical signals to neuronal networks.
Microfluidic systems have the important advantage of commu-
nicating to the neurons with a probably more appropriate
‘‘language’’ of chemical signals and ionic currents rather than
electronic currents. However, they have intrinsic limitations as
implantable devices with respect to liquid storage capacity and/or
their external supply of the neurotransmitters. As an experi-
mental tool for the ex vivo investigation of operations of neurons
and their networks,[297,303] microfluidic system can be exception-
ally convenient, particularly when combined with nanoscale
surface modification,[304,306] and creation of 2D and 3D gradients
of biochemicals affecting neuronal stimulation.[303,306,307]
5.1.1. Nanoscale Electrodes and Inflammation Reactions
Nanoscale NEs have the potential to circumvent reactive
biological responses by virtue of their small size and mechanical
properties (see Section 2.3.3). Specialized techniques resulting in
microscale lesions[308,309] have been successfully employed to
minimize scarring due to acute trauma to the tissue and
vasculature caused by implantation,[98] and it is reasonable to
postulate that these results will also apply to nanoscale implants.
As for glial scarring due to chronic electrode presence, it is
unclear what type of reactive response nanoelectrodes will elicit,
but reasonable assumptions can be made. Decreased effects of
electrode motion due to smaller electrode sizes and less disparity







3984trodes[88,104] should both contribute to a decreased reactive
response to chronically implanted nanoelectrodes.[310] Addition-
ally, nanoscale probes have a unique potential to access neural
tissue without interfering with normal physiological function. For
example, proof-of-concept experiments with sub-micron wires
have demonstrated that NW probes could be introduced via
catheter into the microvasculature of the brain, where their small
dimensions would allow them to innocuously record surround-
ing electrical signals without interfering with blood flow or
normal brain activity.[52]
5.1.2. Nanoscale Electrode Arrays
Continuing the topic of nanoscale electrodes, arrays of NEs,
similar to the MEA in Figure 1G, for example, will also benefit
from reduction of size. Nanoscale NE array technology is an area
of research still in its infancy.[311] Many of the developments in
the field have served to establish reliable processing techniques
for nanoelectrodes.[311] These advances have laid the groundwork
for a wide range of future applications, but critical technical
hurdles remain. One set of challenges is associated with the
physical characteristics of nanoprobes and their need to have
sufficient mechanical strength and toughness—characteristics
that might not be attainable using classical materials.
The task of developing implantable nanoscale NE arrays
containing dense collections of individually addressable nanoe-
lectrodes involves even greater technological hurdles. As
discussed earlier, decreased surface area of miniaturized
electrodes results in dramatically increased electrode impedance.
Additionally, the addressing of individual nanoelectrodes within
large arrays poses a new set of challenges. Nanoscale wires and
interconnects have been developed, but significant break-
throughs in these areas would be required to cope with the
wiring complexities that would be associated with dense NE
arrays. Notably, FETs and NWcircuits offer alternative approaches
for two-way communication with neurons (see Sections 5.7
and 5.8).5.2. Nanoscale Patterning of Electrodes5.2.1. Chemical Patterning
Recent advances in nanotechnology allow one to control neural
interfacing through nanoscale chemical and physical patterning.
The latter refers predominantly to topography and is considered
in the subsequent section, whereas the former encompasses a
variety of cell-adhesive and cell-repellent layers. All of these
strategies can be useful tools in fighting the immune response,
neural depletion around NEs, and, at the same time, make
possible the creation of sophisticated NE-live cell systems and
unique neural devices.
A variety of surfaces have been designed to reduce cell
adhesion, including those modified with self-assembled mono-
layers (SAMs) presenting hydrocarbons,[312] mannitol,[313]
PEG,[314–316] oligoethylene glycol (OEG),[315–317] and fluorinated
hydrocarbons.[318–320] One critical issue is that non-polar surfaces
that inhibit cell adhesion will bind to hydrophobic domains of
soluble proteins and thus may become less effective over 2009 WILEY-VCH Verlag Gmbtime.[315,317] Other surfaces, such as PEG, resist both cell and
protein adhesion but can autooxidize, especially in the presence
of the transition metal ions that are at high concentration during
cell culture.[315] Fluorinated hydrocarbons present an effective
inert surface in conditions that do not contain protein-rich serum
because (i) they are among the most hydrophobic surfaces
achievable by a SAM[318] and (ii) are quite stable under culture
conditions.[319,320] OEG surfaces are also relatively stable and have
been shown to resist cell spreading in protein-rich conditions for
over 1week in culture.[313,316]
Cell-adhesion coatings include factors such as poly(ly-
sine),[179,320] poly(lysine)-conjugated laminin,[321] fibronectin,[322]
and collagen,[323] which can be patterned with nano- and
micron-scale resolution using photolithography or microcontact
printing.[324,325] Such patterned surfaces have been used to direct
the attachment and confined growth of neurons, as well as cardiac
myocytes, fibroblasts, and HeLa cells.
Critical to effective cell patterning is choosing a matrix that
allows cells, often patterned at low densities, to remain viable in
culture and retain the electrophysiological properties exhibited in
bulk culture. In a recent study,[320] sparsely plated neurons were
cultured on patterned polylysine, with neurite growth guided
along micropatterned lines, and several key observations were
reported. First, neurons were shown to be viable for up to 17 days
while maintaining a resting potential and membrane time
constant similar to neurons grown in standard culture conditions.
Secondly, patch clamp electrophysiology was used to demonstrate
that patterned cells exhibit electrophysiological properties similar
to those that are not patterned. Thirdly, both inhibitory and
excitatory neurons were present in patterned networks and were
shown to form interconnected networks with functional
synapses. Finally, given sufficiently long culture times,
the synapses matured and exhibited spontaneous and evoked
synaptic currents. Taken together, these studies[320] indicate that
patterning of adhesion-promoting material presents a general
platform for cell patterning, and specifically, that patterning
of poly(lysine) enables the culture of low-density neurons and
neural networks with guided neurites that exhibit the physiolo-
gical properties of non-patterned neurons.
5.2.2. Topography
Topographic effects have been investigated extensively for silicon
and titanium,[326] and to a lesser extent for polymers, such as
poly(methylmetacrylate).[327] Silicon in particular is commonly
used because of well established lithography tools and protocols,
previously developed for electronics. Methods of patterning of
organic materials, including ink-jet printing, nanoscale imprint-
ing, and PDMS stamping, were developed more recently.
Physical patterning to provide topographic cues offers a potent
means for the control of cell adhesion, migration, orientation,
shape, and even gene expression.[327–336] Though surface
topography and chemistry interact in a complex synergistic
manner,[337,338] topographical cues alone[339] are able to exert
considerable influence over the cells they contact.[257,326,340,341]
Topographic stimuli appear to affect both neural and non-
neuronal cell types, and different topographies exert varying
effects on adherent cells.[294,328,330–335] An approach toward







Figure 7. Alignment of axons of adult mouse sympathetic and sensory
ganglia on horizontally imprinted pattern made by nanoscale contact
printing with different topology. A) 200 nm width and 400 nm pitch. The
arrow indicates the border of the pattern. The more random growth of
axons outside the pattern is clearly visible. Note that the larger axons are
not as well guided as the thinner ones. B) 100 nm width and 500 nm pitch.
C) 400 nm width and 800 nm pitch. SEM images showing that the axons
grow on the ridge edges and not in the grooves. Adapted with permission
from [327]. Copyright 2000, Blackwell.physiological structures that normally interact with the cell type of
interest.
In the simplest case, nanotopography can be altered by
randomly modulating a substrate’s surface features (i.e., varying
its roughness). Modulation of surface roughness is technically
straightforward, and has been applied to enhance the function of
many biomedical materials, including silicon, silica, titanium,
titania, stainless steel, iridium, iridium oxide, and a variety of
plastics used in neural medicine and NEs.[217] Chemical etching
of materials is one method that can be used to pattern surfaces
with roughness at the nanoscale, and has been used to promote
cultured cell adhesion and viability.[342,343] Reactive ion etching
has also been used to create randomly patterned Si column
structures that promoted astrocyte adhesion.[344] Strong neural
attachment to implanted electrodes is desirable as it increases
interface stability and improves electrical transfer across the
tissue/electrode boundary.[343] A plausible mechanism by which
nanoscale surface roughness promotes cellular adhesion is
through increased contact area resulting from cell membranes
conforming to fit the roughened surface.[342,343] An ‘‘average
roughness’’ of 20–70 nm was found to be optimal for promoting
neural adhesion and survival on etchant roughened Si.[342,343]
Similar metrics for other substrate materials and cell types have
yet to be established. It should be noted, however, that roughness
levels are somewhat difficult to define and quantify,[326]
To enable the patterning of neural systems with greater
complexity than a monolayer of randomly connected cells, a
technique for achievingmore controllable nanoscale patterning is
often preferred. Grooved topography is one of the most popular
methods for controlled patterning of neuronal cells due to well
developed nanolithography capabilities, and because directed cell
growth is necessary for a variety of NE applications.[326,339,345]
Neurons tend to attain an elongated shape within grooves due to
surface-induced rearrangements of the cytoskeleton.[346] Neural
growth cones are very sensitive to physical topography, even in
the absence of specific biochemical cues, and this sensitivity can
be exploited to achieve directed growth. It was found that the
majority of cells closely follow grooves and ridges, even over
discontinuities.[327] For example, axons of adult mouse sympa-
thetic and sensory ganglia were shown to display pronounced
changes in the orientation when cultured on horizontally
imprinted patterns (Fig. 7A and B). Different patterns consisting
of parallel grooves with depths of 300 nm, widths of 100–400 nm,
and distances between two adjacent grooves of 100–1600nmwere
investigated. The influence of these patterns appears to be largely
a function of the relation between axon diameter and groove/
ridge width. Axons of peripheral neurons experience the guiding
effect by topographic patterns when the lateral features are
100 nm or larger, which is important to consider when dealing
with patterns made by aligned nanomaterials of smaller
diameters, for instance SWNTs.[18,19,206,347,348] One may also
note that the nerve cell processes preferred to grow on ridge edges
and elevations in the patterns rather than in grooves (Fig. 7C).
This seemingly claustrophobic behavior is potentially
explained by the better nutrient delivery conditions in these
locations.
It is interesting to compare the guidance effects of nanoscale
topographical features with those exerted by chemical pat-
terns.[337] When a range of groove depths from nanometric up toAdv. Mater. 2009, 21, 3970–4004  2009 WILEY-VCH Verlag Gmicrometric was used, it was found that the deeper the groove the
more pronounced were the effects of the topography, so that at the
greatest depths the nanoscale topographic groove effect domi-
nated the chemical track effects.[337]
Considering the potent effects of topography on cellular
behavior, it is no surprise that gene expression is affected by the
nanoscale features of underlying surfaces.[349] The largest study
in this area was carried out using gene arrays and reported that







Figure 8. A) SEM image of aligned poly acrylonitrile-co-methylacrylate
(PAN-MA) nanofibers, B) NF-160 staining of neurite outgrowth from a
dorsal root ganglion (DRG) cultured on an aligned nanofiber film, C) S-100
staining of Schwann cell migration from the same DRG. (Courtesy of I.
Clements, V. Mukhatyar, and R. Bellamkonda, Georgia Institute of Tech-
nology, Atlanta, USA).
3986a result of growing fibroblasts on pillar nanotopogra-
phy.[292,350–352] If this finding applies to neurons, then topography
represents a potentially powerful system for controlling the
phenotype of cells. It is possible that nanoscale topological surface
features induce changes in chromosome territories.[350]
While guidance of axons and neurites by surface topography
and chemistry is feasible and effective, it is perhaps physiolo-
gically more relevant to affect neural guidance via alignment of
supporting cells. Longitudinally oriented glial cells stimulate and
support the parallel growth of axons and neurites[353,354] not only
via physical guidance cues, but also through aligned and
constrained pathways of biochemical guidance cues, such as
secreted ECM molecules.[353] Fibroblasts, meningeal cells,
astrocytes, and Schwann cells, oriented on substrates with
topographically aligned features, have all been shown to
successfully guide neurite and axonal growth.[338,353,355–357]
5.2.3. Additional Techniques for Topographic Patterning for Neural
Tissues
Most studies on the effects of topography on neural tissues have
been performed on substrates patterned with traditional
photolithography (see Section 5.2.2). Several additional techni-
ques, however, each with their own tradeoffs, can be used to
achieve organized nanoscale patterning of a substrate. Electron
beam lithography (EBL), for example, offers precise individual
features, as small as 3–5 nm,[358] but this resolution comes at the
cost of expensive equipment and slow processing.[359] Further-
more, to fabricate patterns across larger surface areas, minimum
feature sizes increase up to around 30 nm.[358] For reference,
fibroblast filopodia have been shown to respond to nanoscale
patterns as low as 35 nm.[292] As a step toward cost efficient mass
production, there are current efforts to replicate EBL patterns by
employing molds and nanoimprint lithography.[292,359]
A wide variety of simpler and more cost-effective techniques of
achieving controllable nanoscale substrates are also available.
Technologies such as dip pen nanolithography[360] and electro-
static atomic force microscopy[361] can be used to deposit or detect
individual molecules to pattern and to characterize nanoscale
materials. Neural cells have been cultured on surfaces patterned
by these approaches with true nanoscale features, and specific cell
adhesion and growth patterns were shown to result within
specific ranges of nanoscale physical structures.[342,362–364]
Simpler technologies for nanoscale patterning exists as well,
but they typically come at the cost of specific feature
geometries.[359] For example, the technique of electrospinning
can be used to create aligned layers of polymer fibers of nanoscale
diameter.[365] Briefly, a high voltage is applied between the tip of a
syringe as it slowly ejects a liquid polymer melt and a collecting
surface. The collection of charge on the syringe tip causes
repulsive forces resulting in the ejection of ‘‘nanofibers’’ that are
projected toward the collecting surface. One method of achieving
alignment of the nanofibers is to use a high-speed rotating disk or
drum as the collecting surface. The resulting aligned nanofibers
have been shown to direct glial alignment and promote directed
growth of neurites and axons (Fig. 8).[366–369] Aligned nanofiber
scaffolds are thought to mimic the structure of collagen, a major
component of extracellular matrix, by creating fibrous networks
that provide structural strength and support cell growth.[359] 2009 WILEY-VCH Verlag GmbSeveral types of regeneration scaffolds employing electrospun
nanofibers at their core have been shown to effectively facilitate
nerve regeneration in vivo. As an example, one such construct[370]
consists of a semipermeable tube containing stacked film layers
of aligned nanofibers, and has been shown to promote axonal
regeneration with an effectiveness approaching that of auto-
grafted nerve segments, the current clinical gold standard.[371]5.3. Model System for Replication of Neural Networks
Understanding of information processing in neural networks and
tissues is critical for understanding mechanisms of treatment
and designing more efficient NEs. For that reason, it would be of
value here to discuss briefly some simple model systems to study
signal processing in neuron networks. They can be quite
interesting from the perspective of utilization of nanotechnology
capabilities in fundamental neurology. Incidentally, they are also
intimately related to the patterning of electrodes with nanoscale
features described in the previous section.
The simplest models are based on geometrical patterns of
neurons created on substrates using chemical and/or topogra-
phical cues presented above. Starting with predominantly
microscale patterns, poly(dimethylsiloxane) molds have been
used to study neuron-astrocyte communication by designing
experiments that control when and how cells grow and signal
each other, which allows dissecting apart the molecular details of
complex signaling.[372–375] By plating neurons in one well and
neural astrocyte cells in adjacent wells, chemical signaling via
soluble factors that diffused from well to well could be
studied.[372–375] Similarly, by creating specific patterns using
substrates on which cell processes can grow, and discouraging
cell growth outside of these patterns using materials which cells
cannot adhere to, hypotheses about the cellular mechanisms of
neuronal signaling have been successfully investigated.[372–375]
Using the guiding effect of topographic features, one can
create fairly complex patterns of neural cells.[376,377a] Particularly
fascinating are the patterns where the cells are interconnected
with each other in a controlled fashion represented by Figure 9G,







Figure 9. A) A SEM image of an engineered neural network. The dashed circles mark the
polylysine islands used to define the network. B) Each of the cell clusters contains hundreds of
cells and extends between 1 and 8 bundles. C–F)Multiple staining of two interconnected clusters.
C) DAPI, cell nuclei. D) NFM, the bundle connecting them is composed of axons and dendrites.
E) MAP2, neurons. F) red, axons; green, dendrites; blue, cell body. The yellow color arises from
coincidence of green and red fluorescence (from [336]). G) Neuronal network made from 76
neurons growing on the matrix of standard 64 electrodes. Adapted with permission from [377b].
Copyright 1994, Academic Press.vivo models of neural networks existing in neural tissue and (ii) a
network of NE pads with single cell excitation capabilities. The ex
vivo models can serve both for understanding of signal
transduction, stimulation effects (see Section 2.3.5), and drug
discovery. It should be appreciated that though the growth cone(s)
may conform well to the substrate, the axon or dendrite following
behind may adhere poorly to the substrate. So, if the extension is
mechanically strained by the route followed, as for example by
attempts to turn acute angles, the main part of the neurite may
contract and pull the neurite into the shortest path. In some
instances, even the cell body may be detached and the cell is then
left ‘‘suspended’’ between two or more growth cones or a growth
cone and the cell body. For these reasons, the most stable patterns
of neurons are orthogonally or hexagonally intersecting paths.
Such considerations might account for the preference of axon
extension or bifurcation to be about 608. Other patterns might be
sufficiently stable mechanically, but do not seem to have been
used. The 608 and related pattern represents a rudimentarymodel
for information flow and processing.[378]
Patterning of neurons in 2D networks can be achieved via
anchoring of cell clusters at specific positions without any
interconnects between the islands or pads.[336] The compact
connections among pairs of islands occur spontaneously through
a single non-adherent straight bundle (Fig. 9). The 100mm in
diameter islands that stabilize the location of cell clusters can be
both chemical and topological. The islands and pads were made
of poly-D-lysine or CNTs, respectively. Multiple staining indicates
(Fig. 9C–F) that there are no cell bodies in the interconnecting
links.[336] Monitoring the dynamics of the forming networks in
real time revealed that the organization of the neural network is
mainly driven by the ability of the neuronal cell clusters to move
away from each other while continuously stretching a neurite
bundle in between. The resulted network patterns are very stable
and can be maintained for as long as 11 weeks.[336]Adv. Mater. 2009, 21, 3970–4004  2009 WILEY-VCH Verlag GmbH & Co. KGaA, WeinAlthough neural networks with square,
triangular and circular geometry were rea-
lized,[336] not only the size (x, y, and z
dimensions) of the nanoscale features but
also the array pattern (i.e., orthogonal, hex-
agonal and random and other patterns) affects
adhesion.[379] It appears that cells prefer a
pattern of particular symmetry. Though such
tests have not yet been done on neurites, it is
almost inherently obvious that there will be
such effects because the fine processes con-
forming to the packing and spacing of the array
are of similar size to the pillars (or pits). This
suggests that misalignment of the arrays will
lead to unintended routings, but it also
indicates that the alignments of these NPs
and related nanoscale features could be used to
construct complex and precise nerve networks
in the model neural structures.5.4. Drug Delivery Layers on Electrodes
Biochemical coatings on the surfaces of NEs
allow for modulation of the local tissue response while improving
cell attachment and electrode performance. Dexamethasone, for
example, is a synthetic glucocorticoid hormone that has been
coated on implantable electrodes to reduce glial scarring and
neuronal loss.[380–383] Coatings not only enable precise localiza-
tion of drug release, but can also offer sustained release over time.
New techniques in nanotechnology allow for the fine control of
coatings with thicknesses down to the nanoscale. These
capabilities are important for fine-tuning drug delivery, and also
for decreasing the overall thickness of coated probes in order to
minimize the inflammatory response.[12]
Layer-by-layer (LBL) assembly is an example of a process that
can be used to produce film coatings with precise thicknesses on
the order of nanometers.[384] Briefly, LBL assembly exploits
secondary interactions between macromolecular species to
sequentially build the coatings one nanometer layer at a time.
The most common realization of LBL is the combination of two
oppositely charged polyelectrolytes.[385] Cyclic repetition of
adsorption steps using polyelectrolytes of alternating charge
can be used to yield multilayered structures of arbitrary
thickness.[384] Due to the fact that these processes are largely
unconstrained by the nature, size, or topology of the substrate,[384]
LBL assembly is highly versatile and has been used to deposit
bioactive coatings on implantable electrodes for a wide range of
biosensing applications,[386] for electrical neural interfa-
cing,[16,183,203] and recently, with neural stem cells (NSCs).[387]
For example, nanoscale coatings of laminin on silicon wafers have
been shown to enhance attachment and differentiation of cortical
cells cultured on the wafer surface.[385] In another set of
experiments, chronically implanted silicon microelectrode arrays
coated with nanoscale laminin layers were shown to elicit a
decreased gliotic response after 4 weeks in vivo.[388] Significantly,
the integrity of these coatings was not compromised by the shear







3988LBL coatings had no observable effect on electrode impedance
around the biologically relevant range of 1 kHz.[385] LBL
techniques have also been used to embed anti-inflammatory
agents such as piroxicam and a-MSH.[389,390]Figure 10. SEM image of NE from conducting polymer. Reproduced with
permission from [394]. Copyright 2001, Elsevier.5.5. Electrical Coatings on Electrodes
Nanostructured materials can provide an excellent foundation for
NE design focused on improving charge storage capacity and
reduction of electrode size. In the realm of organic nanomater-
ials, the most significant strides in this direction were made
with conductive polymers,[391] exemplified by poly(3,4-
ethylenedioxythiophene) (PEDOT). Through electrochemical
deposition, these conductive polymers can be precisely localized
to active electrode sites with coating thicknesses down to the
nanoscale.[392,393] As compared to purely metallic electro-
des,[112,394–401] electrodes coated with conducting polymers
provide a more adaptable interface with neural tissue with
smaller hardness mismatch. The best examples of polymer-
coated electrodes made from poly(pyrrole) (PPy) or PEDOT can
also significantly decrease the impedance of microelectrodes at
1 kHz by about two orders of magnitude and increase the charge
transfer capacity of microelectrodes by three orders of magnitude
in comparison to bare Au electrodes.[357,370,392,402] Although Au
electrodes do not have the best electrical characteristics as NEs
(see Section 2.2), and in fact, far inferior in respect to charge
injection capacity to other materials, they are often used for
comparative reasons due to simplicity of preparation and
availability. To a large degree, the improvements mentioned
above are attributed to the NT morphology of this material
(Fig. 10), which is molded by sacrificial electrospun fibers that
are subsequently dissolved after coating with PPy or PEDOT.
(Later similar morphology can be seen in CNT electrodes (see
Section 5.6).) It is still difficult, however, for PPy and PEDOT to
exceed charge injection capabilities of IrOx.
[403] Additionally, the
conductivity of conducting polymers is not as high as one would
want it to be (300 S cm1) comparatively to metals and they have
to be used on conductive (metallic) substrates. So, the same issue
of mechanical mismatch and likely activation of reactive
astrocytes by micromotions of the electrode are still present.
Improvement of the electrical characteristic of the immediate
interface between the electrode and cells is important, but it will
not benefit the long-term implants unless a solution for electrode
encapsulation is found. This holds true for stimulation of deep
brain areas, spinal cord, the eye, and peripheral nerves.
Additionally, conductive polymer coatings can be doped with
biological agents to minimize tissue reaction and promote neural
growth and adhesion. NGF and extracellular matrix proteins, for
example, have been localized directly to electrode sites to enhance
neural growth and adhesion.[357,404,405] Furthermore, biological
agents can be incorporated into the conductive coatings such that
their release can be controlled over time via electrical stimula-
tion.[392,406] In one study, for example, an anti-inflammatory agent
was mixed within a degradable polymer that was electrospun into
a 3D structure of nanoscale fibers on the surface of a neural
probe.[392] Conductive polymer was then deposited to coat this 3D
nanotubular structure, and subsequent electrical stimulation via 2009 WILEY-VCH Verlag Gmbthe conductive polymer caused it to contract, expelling the
anti-inflammatory agent in time-controlled bursts.5.6. Carbon Nanotube Materials for Neural Electrodes
Many challenges facing current NEs (see Section 2.3) are related
to mechanical and electrical properties of the electrode materials.
The extraordinary strength, toughness, electrical conductivity,
and surface area of CNTs make them excellent candidates for
interfacing with neural systems for the development of
biocompatible, durable, and robust neuroprosthetic devices.
Mechanical compliance of highly conductive CNT composites
with tissue can substantially reduce micromotions, suspected to
activate the resident immune cells in neural tissues, and hence
resulting in glial scarring (see Section 2.3.3). High surface area
can drastically increase charge injection capacity[204] and decrease
the interfacial impedance with neurons, which is exactly what
further miniaturization of electrodes requires. Smaller size of
NEs will also reduce inflammatory response. Besides that, CNT
coatings can also reduce delamination of electrodes from their
underlying substrate, removing one of the significant technical
issues with IrOx electrodes. The samematerials can also function
as FET elements in the structures similar to those manufactured
from Si described in Section 5.7 Additionally, the abundance of
CNT derivatives involving biological components, such as
peptides,[407,408] proteins,[408–411] and DNA[408,412–414] also allows
one to consider them as a potential player in drug delivery and
treatment of CNS disorders,[154,188,190,415–419] performing to
some degree the functions of organic nanostructures described
above.
The current state of the development of CNT/neural interface
is far from the complete realization or even understanding of
promising properties of NTs in respect to NE engineering. In
2000, it was suggested that CNTs could be used as substrates for
neuronal growth.[151] Scanning electron microscopy (SEM) was
used to identify the morphological changes of neurons brought
about by MWNTs. The neuronal bodies were found to adhere to
the CNTsurface with neurites extending through the bed of CNT
and elaborating into many branches. The neurons remained alive
on the NTs for at least 11 days, and it was shown that several
chemical manipulations on the MWNT enhanced neurites
growth and branching. After this first report, several groups
developed methods of neuron culture on CNT
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films monitored using traditional fluorescence techni-
ques.[200,202] The numbers of neurites were counted depending
on the nature of the NT and their functionalization. Using
hippocampal neuronal cultures, neuronal growth was system-
atically controlled by functionalizing MWNTs with different
chemical groups and the morphological features of living
neurons were characterized. Using these CNTs as scaffolds for
neuronal growth, it was found that neurons grown on positively
charged MWNTs showed more growth cones together with more
successful branching, thus simple variations in electrostatic
charge on MWNTcould manipulate neuronal growth patterns. A
related question is whether CNTs, simply due to their intrinsic
structure, can directly improve the functional rewiring of
disconnected neuronal networks.
The simple CNTcoatings made by drying or growth in vacuum
used in previous studies are intrinsically fragile. They are likely to
degrade and delaminate over time, resulting in the same issues as
currently used electrodes if not more severe ones. The first steps
toward utilization of both electrical and mechanical properties of
SWNTs in neuroprosthetic devices were made with NTs films
assembled using the LBL[16,19,203,385] or other methods of making
NT composite coatings with considerable adhesion to the
substrate and NT content significantly above the percolation
limit. The layering with polymers method allows one to control
the structure of CNT–polymer composites and incorporate both
high conductivity and high strength in one material.[348,421–423]
The SWNT substrate was prepared by LBL layering with a
negatively charged polyacrylic acid polymer (PAA) and SWNT
coated with positively charged poly(N-cetyl-4-vinylpyridinium
bromide-co-N-ethyl-4-vinylpyridinium bromide-co-4-vinyl-
pyridine).[19] It was demonstrated that cell cultures of
NG108-15 effectively grow and proliferate on these substrates.
Moreover, the number of neurites spun from individual cells
exceeds those developed on traditional cell growth substrates.
The next advance in neuron–NT characterization came from
the measurement of spontaneous postsynaptic currents (PSCs)
from a single neuron.[152] The appearance of PSCs provides clear
evidence of functional synapse formation and is a widely accepted
index of network efficacy. The NTs used for neuronal growth were
first functionalized and then deposited from a dimethylforma-
mide solution; after evaporation, the NTs were defunctionalized
by thermal treatment leading to glass slides covered by a film of
NTs. Hippocampal neurons were attached and cultured on
purified MWNT. This strategy allowed a long term and stable
retention of films of CNTs on glass and, moreover, a long term
neuronal cell culture. Hippocampal neurons grew and attached to
the purified CNT film and extended several neurites, forming a
net morphologically similar to that developed under control
(CNT-free) growth conditions in terms of cell numbers and neural
processes, as verified by scanning electron microscopy and
immunocytochemistry. Neuronal cell bodies displayed normal
morphology and dimension as well.
The focus of that investigation was then shifted to the
functional properties of brain circuits grown integrated to a CNT
substrate, by performing single-cell patch-clamp recordings. By
this technique it is possible to monitor single-cell and network
generation of electrical activity. Since neuronal activity is
ultimately electrical activity, electrophysiological recordings allowAdv. Mater. 2009, 21, 3970–4004  2009 WILEY-VCH Verlag Gmonitoring of the efficacy of a brain network in processing
information. The appearance of synapses, revealed by PSCs
generation, provided clear evidence of functional network
formation. Under these experimental conditions, the CNT
substrate strongly increased the average PSCs frequency together
with the frequency of spontaneous action potential generation in
all recorded neurons when compared to control ones. Thus,
growing neuronal circuits on a CNTs platform promoted a
significant increase in brain network operation. Such an effect
was not related to CNTs increasing the number of surviving
neurons, suggesting that enhanced network activity was
apparently related to a potentiated synaptic function more than
an increase in the number of synapses.
Recent reports indicate the possibility to directly stimulate
isolated neurons via CNTs in culture.[16,206] In 2008, the same
observations were made in primary cell cultures, and actual
tissues of rats and monkeys.[420] It was also indeed demonstrated
that coating of metal electrodes with CNTs led to low impedance
electrodes,[420] however little or no explanation in this work was
given about origin of such effects. Little is known about the
electrical features of such a coupling, or the possibility to evoke,
via purified CNT substrates, synaptic activity in long term neural
circuits. The early studies indicated that extrinsic electrical
stimulation through the SWNT induced the appearance of
cell inward currents that were indistinguishable from those
elicited via direct IC application of voltage steps.[16,206] In
SWNT-polyelectrolyte coatings, the stimulation of inward
currents with a cathodic extrinsic stimuli suggested that cells
were activated from current leakage into the bath via a resistive
coupling to CNTs. Electrophysiological measurements indicated
electrical excitation of neurons when current was passed through
the SWNTcoating, not distinguishable from traditional neuronal
excitation associated with opening of classical voltage-gated cation
channels.
Additional work[208] employed electrophysiology and computa-
tional modeling in order to understand the nature of electrical
coupling between neurons and pure SWNTs. The recordings
suggested that coupling between neurons and SWNTs might in
fact be at least in part resistive; further studying involved
mathematical modeling. This combined approach implicated that
any resistive coupling between bio-membranes and SWNTs is
qualitatively indistinguishable from a coupling between SWNTs
and the patch-pipette through the patch-seal path to ground.[208]
Thus, whole-cell patch clamp recordings from neurons stimu-
lated by SWNTs may yield deceiving results. Hence, due to the
non-idealities of the single electrode voltage clamp, eliciting
Naþ-currents in neurons through SWNTs stimulation does not
conclusively prove a resistive coupling between SWNTs and
neurons. Rather, this can be accomplished by detecting synaptic
responses, such as evoked by action potentials elicited in
non-clamped neurons using the electrical stimulus delivered
via SWNTs.[208]
We need to mention that, electrical properties of SWNTs make
them also suitable for capacitive stimulation of neurons and their
functionalization may be instrumental in establishing cell/
surface interactions affecting the coupling mechanism. Capaci-
tive coupling, in our opinion, will be a more efficient way to excite
neurons more conductively with long-term function of implan-







3990Another recent development in CNT-based devices is
represented by the design of multi-electrode arrays (MEA) to
both electrically stimulate and record from neurons. Such MEAs
were made by synthesizing islands of high density CNT on
lithographically defined, conductive substrates.[424,425] Both
multiwalled and single walled CNT structures are being used
as microelectrode neural interfaces following chemical functio-
nalization.[204,258,426] For example, proof of concept stimulation of
hippocampal neurons has been demonstrated using vertically
aligned hydrophilic functionalized CNTs electrode arrays.[204]
Advantages of MEAs over the traditional metallic ones are
manifold and were, by and large mentioned when discussing
normal electrodes. CNTs can drastically increase the charge
injection capacity while further reducing the size, reduce
inflammation, and provide uniquely biocompatible surface.
However, we also have a concern over the mechanical integrity
of microelectrodes at the point where CNTs are growing from the
substrates. The forces applied by the cells during the micromo-
tions to these points are expected to be quite large, which can
threaten the integrity of MEAs and generate debris around the
electrode.5.7. Interface of Traditional Field Effect Transistors and
Neuronal Cells
Starting from the 1950s advances in neuro-electronic systems
were related to the progress in electronics industry and circuitry
processing. To a large degree, one can trace this trend in the
utilization of silicon etching technologies and lithographic
techniques to the development of Michigan and Utah electrodes
(Fig. 1). Their success is based entirely on the excellent degree of
control achieved for silicon processing during the development of
electronic circuitry and MEMS devices.
In that respect, one of themicroelectronic devices that attracted
the most attention in the last decade for neuronal interfacing is
the field-effect transistor (FET). FETdevices for neural interfacing
were initially developed to enable the study of signal processing in
arborized neurons and neural networks.[427] One of the main
obstacles during the course of development of intracellular (IC)
recording techniques of electrical activity in neurons was the
simultaneous recording of signals from multiple neurons.
Whereas voltage-sensitive dyes[428] allow rapid changes in
membrane potential of neurons to be detected and measured
from multiple sites, selective measurements are impossible and
the toxicity of the dyes, when illuminated, make them unsuitable
for long-term recording.[377,429] IC recordings with glass pipette
electrodes and the patch-clamp method measure potential by
penetrating the cell membrane with a micropipette to create a
connection with low electrical resistance.[430] Not only is this
method invasive, but the contact between cell and electrode is
difficult to maintain longer than several hours, needless to
mention the difficulty for attachment of multiple electrodes.[431]
With the arrival of a complementary system consisting of a
microscopic silicon element with perfectly insulating silicon
oxide, it became possible to stimulate a neuron extracellularly by
capacitive coupling through a silicon chip in 1995.[432] The
development of the FETas a neural interface device was predated 2009 WILEY-VCH Verlag Gmbby the manufacturing of sophisticated probe sites on Michigan
electrodes, which possess a very convenient lay-out for
manufacturing.[44,433,434] Placement of the FET on the NE but
not on the recording site allowed the researchers to combine the
sensitivity of FETs and low-noise operations. Also, manufacturing
of neural interface sites with an insulating Si3N4 layer, although
still inmicrometer scale, for implantation in peroneal nerve trunk
of a rat was reported in 1991.[435] In 1996, the complementary
metal oxide silicon (CMOS)-compatible technology was also
applied for manufacturing of sophisticated on-chip circuitry for
signal processing,[436] while integration of FET and recording
sites on NEs was reported in 2000.[437]
FET devices allow stimulation and recording on cultured
neurons to be conducted in a non-invasive manner. All FETs have
four terminals: the gate, drain, source, and substrate (Fig. 11A).
The gate permits or blocks the flow of electrons by creating or
eliminating a channel between the source and drain. Because a
current is generated from electrons flowing from the source
terminal toward the drain terminal in response to an applied
voltage, the device allows the extracellular voltage of individual
neurons attached to the gate terminal to be detected and
measured. One of the earliest examples using an identified
neuron of the leach attached to the non-metallized open gate of a
FET demonstrated that the action potentials modulate directly
with the source–drain current in silicon through capacitive
coupling.[427] Unlike previous attempts to measure potentials
using electrodes,[438,439] the FETdevice allows detection of signals
below the threshold level and its response preserves the shape of
the action potential. From this work, it was postulated that
long-term,multi-site recording of the electrical activity of neurons
at high resolution and high signal-to-noise ratios could be feasible
by constructing patterns of FETs and with further engineering of
the microelectronic circuitry.
The possibility for two-way, non-toxic communication between
microelectronic FETchips and nerve cells was eventually realized
using a hybrid circuit of a semiconductor chip with synaptically
connected neurons from the snail (Fig. 11B).[440] The silicon–
neuron–neuron–silicon circuit begins with a capacitive stimu-
lator on the chip that excites a specific neuron. Signals are then
transmitted in the neuronal network and elicit an action potential
in the second neuron, whose postsynaptic excitation modulates
the current of a FETon the chip. This achievement is a critical and
fundamental step in neuroelectronic engineering and has
immense significance in neuronal signal processing, neurocom-
putation, and neuroprosthetics.
It is no surprise that very few experiments have been carried
out using mammalian cells in the development of neuroelec-
tronic FETdevices.[377,429,441,442] Most of the work to this date has
been conducted using individual or a small network of
invertebrate nerve cells for several reasons.[427,432,440,443–445]
Most obviously, invertebrate nerve cells have large cell bodies
to support efficient interfacing and allow convenient manipula-
tion. This is especially true for works involving impaled
electrodes.[427,432] Working with smaller mammalian neurons
and a larger network of cells requires progress in several key
areas.[440] Stimulators with higher capacitance and transistors
with lower noise are needed to stimulate and record from the
smaller mammalian neurons. The ability to control neuronal







Figure 11. A) Schematic cross-section of a neuron on a buried-channel FET with blow-up (drawn
to scale) of the contact area. During an action potential, current flows through the adhering cell
membrane and along the resistance of the cleft between chip and cell. The resulting extracellular
voltage in the cleft modulates the source–drain current. Adapted with permission from [449].
Copyright 2005, Wiley-VCH. B) Neuron silicon chip. Micrograph of neuronal cell bodies (dark
bodies) in picket fences on a circle of two-way contacts connected by neurites (bright threads)
after 2 days in culture. Reproduced with permission from [440]. Copyright 2001, National
Academy of Sciences. C) Silicon chip with topographically controlled neuronal network on a
4 4 array of bi-directional electronic contact. An optical microscopy image after 2 days in
culture. Details are illustrated in the magnified inset image. Adapted with permission from [445].
Copyright 2005, Wiley-VCH. D) Colorized electron micrograph of a hippocampal neuron on a
silicon chip with linear array of p-type buried-channel transistors after 8 days in culture. Between
source and drain leads are the open voltage-sensitive gates. The surface of the chip is chemically
and structurally homogeneous, consisting of silica with a surface profile below 20 nm. Adapted
with permission from [449]. Copyright 2005, Wiley-VCH.synaptic junctions and the application of very large scale
integration (VLSI) technology are necessary to fabricate chips
with a large number of contact sites for manipulation of larger
neural networks.
Some of the most recent developments in planar neuroele-
tronic FET devices were made possible by advances in chip
fabrication technology. Electrical imaging of neuronal activity of
individual neurons and neuronal networks was mapped at a
resolution of 7.8mm using a 1mm2 array of 16384 sensor FETs
fabricated by an extended CMOS technology.[446] The large
number and high density of recording sites made by VLSI
technology allowed electrical imaging to be obtained non-
invasively at a sub-cellular resolution without positioning and
immobilizing individual neurons at specific locations of the
substrate. This is a significant breakthrough since previous
designs using electrolyte-oxide-semiconductor (EOS) FETs could
only achieve a maximum resolution of 4mm in one dimension
due to spatial constraints with routing the contact wires. The
two-dimensional multi-transistor array was also applied to
cultured brain slices to yield time-resolved images of electrical
field potentials, demonstrating the ability of the new chip to
interface large neuronal networks.[447] Another key development
is the establishment of a neuronal memory on a silicon chip byAdv. Mater. 2009, 21, 3970–4004  2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinjoining an excitatory chemical synapse
between a pair of identified neurons with
the silicon chip.[448] With repetitive capacitor
stimulation on the presynaptic cell, the
strength of the soma–soma synapse can be
enhanced and successfully recorded by a
transistor located at the postsynaptic cell. This
demonstration has significant implications for
the development of biochips for chemical
interfering with synaptic activity, as well as for
integration of electronic circuits with neuronal
activity.
The ability to control neurite outgrowth has
also enabled the interfacing of a geometrically
defined network of neurons to a semiconductor
chip (Fig. 11C).[445] By using topographical
structures for cell immobilization, problems
associated with guidance by chemical pattern-
ing such as insufficient adhesion and detach-
ment of cell bodies (see Section 5.2.2) were
circumvented. The combination of defined
networks and extracellular interfacing made
possible the supervision of network activity at
the single-cell level. Finally, it was recently
demonstrated that local transistor recording of
individual mammalian neurons is feasible with
EOS FETs that have a sufficiently low noise level
(Fig. 11D).[442] By taking advantage of the,
so-called, buried channel design, which sub-
merses the electron channel of the transistor a
few nanometers from the interface in the
silicon substrate (Fig. 11A), it was possible to
reduce the low-frequency noise caused by
electron tunneling between silicon and traps
in the gate oxide. The overall design produced a
signal-to-noise ratio that is sufficient for broad-band recording of the small signals from mammalian neurons.
This was unachievable with previous chip designs.
Neuronal interfacing via FETdevices has the key advantage that
this technique does not interfere with cell activity and affords
long-term recording. By combining complementary microcircuit
elements in chip design, it is possible to non-invasively interface
individual neurons in both directions on a single chip. Recording
at high resolution and high signal-to-noise ratios is possible but
interfacing withmammalian cells will require additional progress
in fabrication technology, material science, and biotechnology.
The technology of neuroelectronics is likely to continue to benefit
from the ever-expanding knowledge available in semiconductor
technology, producing increasingly intricate and useful devices.
FETs, however, are not without disadvantages especially in
comparison with Michigan and Utah electrodes. Overall, they do
not provide the performance comparable to the currently used
electrodes due to high noise. In general, simple metal recording/
stimulation sites connected to shielded FETs located at the base of
an NE shank by an interconnect, should be able to give a better
functioning device. The stability of cellular contact with FET is an
important issue and is likely to prevent such devices from being
used in in vivo experiments and in clinical settings. The intrinsic







Figure 12. A) Schematic of single device/neuron patterning motif used for
axonmeasurements. B) Arrays of axons with growth guided across an array
of NW devices. Yellow asterisks denote locations where an axon was
successfully guided between source and drain electrodes. Scale bars are
50mm. C) A different neuron pattern where neurites are guided to form one
NW/axon junction (red arrow) and two NW/dendrite junctions (blue
arrows). Scale bar is 50mm. D) Schematic of interconnected neuron motif.
E) SEM image of fixed neurons exhibiting a neural network where soma are
interconnected and neurites are interfaced with multiple NW devices
(red arrows). (Inset) Zoom depicting an axon (yellow dotted lines) guided
between source and drain electrodes and across a silicon NW (blue arrow).
B,C) Adapted with permission from [20]. Copyright 2006, AAAS. D,E)
courtesy of Prof. C. Lieber, Harvard U. Boston, MA, USA.
3992geared toward the study of neuronal signal processing and basic
neuroscience research rather than the development of prosthetic
devices. Experiments have seen inconsistent results due to variable
strength of neuron-chip coupling and cell damage during the
isolation process. Satisfactory recordings are highly dependent on a
tight seal of the cellmembrane and gate which is difficult to achieve
at high consistency. Progress must be made in the development of
better capacitors and transistors in order to enable interfacing with
large networks of mammalian neurons at high resolution.
5.8. Nanowire Field Effect Transistors for Neural Interface
NW-FETs have been shown to be highly sensitive detectors of
changes in local charge or electric field,[20,411,449–453] an important
property that can be utilized in NEs. The sensitivity and selectivity
of chemically modified NW-FETdetectors have been demonstrated
for a variety of detection modalities including reversible binding
and unbinding of virus particles (single-virus level)[411] and
proteins (as low as 100 fM).[452,453] The latter figure represents a
sensitivity limit 104–109 times below that afforded by sta-
te-of-the-art ion sensitive planar FETs.[454–456] Given the exquisite
sensitivity of NWdevices and the data provided in the section above
on traditional FETs,[457–462] it would be logical to test NW FETs for
detection of neural activity. Significantly, NW FETs can be used for
measurements from extremely small areas of neurons, for instance
at or below the level of a single axon or dendrite. Moreover, the
junction with the neuronal membrane can be tighter than in the
case of planar FETs since the curvature of NWs allows them to
protrude between the topological features of the cellular
membrane. On a perfectly flat surface this gap is on the order
of tens of nanometers, which is considered to be the result of the
finite length of adhesion proteins,[455] although it could possibly
include other contributions as well. Decrease of this gap is possible
when a nanoscale cylinder makes contact with the cell membrane
as was recently demonstrated in the case of CNTs and a supported
lipid bilayer membrane.[463] In the specific case of cells, it is worth
noting that the nanoscale topology of NWs may serve to promote
adhesion; it was shown that nanostructured surfaces formed by
CNT networks promote cellular adhesion and spreading, even in
the absence of standard adhesion factors such as polylysine.[425,464]
Efficient design of hybrid nanoscale nanoelectronic/cellular
interfaces requires a fabrication scheme that incorporates (i) NW
device arrays with controllable structures and reproducible
electronic properties, (ii) inert surface regions that prevent the
adhesion of cells and formation of unwanted networks, and
(iii) areas containing cell adhesion promoters that will mediate a
tight junction between the cell and NW devices. Ultimately, the
process of heterogeneous surface patterning must be compatible
with already-fabricated NW devices.
NWdevice arrays suitable for NEs can be fabricated by aligning
silicon NWs on the oxide surface of a silicon/silicon oxide substrate
using either Langmuir–Blodgett or dry transfer techniques.[465,466]
Both methods yield highly aligned NWs with pitch that can be
rationally varied between tens of microns to as small as tens of
nanometers. A true advantage of this technique, which outlines a
strength of bottom-up assembly in general, is that bymultiple steps
of partial passivation of the substrate (e.g., with photoresist)
followed by NW deposition and removal of the passivation, it is 2009 WILEY-VCH Verlag Gmbpossible to define regions with distinct NW materials on the
substrate. Similar or distinct NWs, for example p-type and
n-type materials, can thus be readily fabricated into functional
device arrays using photo- or electron-beam lithography, followed
by metallization and dielectric passivation of the metal regions.[20]
The device pitch is defined by NW spacing and the design of the
lithography pattern; device arrays with pitches from more than
50mm to 400nm and below can be fabricated using this approach.
In the case of these experiments, the surface of the NWdevices
was patterned with standard photolithography techniques using a
combination of poly(lysine) and SAM-forming fluorinated silane
as the cell adhesive and cell-repellent factor, respectively (see
Sections 5.2.1 and 5.3). Using these bi-functional coatings,
isolated neurons can be directed to extend neurites in a specific
direction(s) crossing single NWdevices (Fig. 12A). More complex
patterns can also be created; examples include axons and
dendrites crossing multiple NW devices that can serve as
multiplexed inputs and outputs (Fig. 12C) and interconnected
neural networks with neurites crossing an arrays of devices
(Fig. 12D and E).[20]
Action potential signals can be measured in NW-FET
electrodes interfaced with an axon. These measurements can
also be benchmarked against IC potentials measured with a
conventional glass microelectrode impaled in the soma. Direct
temporal correlation between IC potentials and the signal
recorded from the p-type NW was observed. Such behavior is
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potential) and causes carrier accumulation (increased conduc-
tance) followed by depletion (decreased conductance), consistent
with previously reported measurements from mammalian
neurons interfaced with planar FETs.[442] A variety of controls
served to validate these measurements.[20] First, it was observed
that an increase in depolarizing current results in an increased
frequency of signals measured by the IC electrode and NW FET.
Secondly, an NW-axon junction failed to record signals after the
axon was severed, although signals continued to be elicited in the
soma. Finally, a set of electrodes with no NW recorded no signal
from a growth-directed axon. Taken together, these controls
demonstrate that extracellular recordings are a result of carrier
modulation in the NW that is caused by changes at the local axon/
NW interface.
In addition to recording, stimulation of neurons at highly
localized regions represents a useful technology since it could
enable multiplexed nanoscale inputs that might be operated as
‘‘artificial synapses.’’ The NWdevices were used to apply biphasic
excitatory pulse sequences to create detectible somatic action
potential spikes measured by a microelectrode, a process that
could be a result of capacitive coupling developed for traditional
FETs[17,460,467] or highly local, reversible electroporation.[468] The
excitation shows a threshold of about 0.4 Vand no potential spikes
were recorded in the presence of tetrodotoxin, a common Naþ
channel blocker that has been shown to completely inhibit action
potentials as measured by multi-electrode arrays.[469]
Furthermore, NW-based electrodes make possible simulta-
neous measurement of axon/dendrite signal propagation, which
represents a new level of integration that can be achieved with
electronic devices. A device structure consisting of a linear array
of 4-NW FETs, a gap, and 5-NW FETs was designed (Fig. 13) to
investigate simultaneous and temporally resolved propagation
and back propagation of action potential spikes in axons and
dendrites, respectively.[20] An optical image (Fig. 13) demon-
strates well-defined growth of rat cortical neurons with the cell
body localized in the gap and an axon and dendrite guided in
opposite directions across the two linear NW FET arrays. The
specific polarity of growth (e.g., axon across the 4 or 5-FET array)
is not controlled, but is readily identified by the faster growing
projection (the axon) during culture, and subsequently by
electrical response and postmeasurement fluorescent imaging.
Multi-NW/neuron arrays were used to simultaneously detect
conductance output from NWs following IC stimulation at the
soma.[20] Importantly, alternating p- and n-type NW elements
along a single axon can be integrated in one device. Following IC
stimulation of action potential spikes in the soma, temporally
correlated, alternating conductance peaks/dips in NW elementsFigure 13. Optical image of a multi-NW/neuron arrays made from a cortex
neuron with axon and dendrite aligned in opposite directions. Reproduced
with permission from [20]. Copyright 2006, AAAS.
Adv. Mater. 2009, 21, 3970–4004  2009 WILEY-VCH Verlag Gwere observed. These results are consistent with gating of the p-
and n-type NWs by the change in membrane potential associated
with the propagating action potential, and show that we can
generate complementary signals in the hybrid structures.
Stimulation of action potential spikes in the soma yields
correlated conductance peaks in NW elements forming the
NW/axon and NW/dendrite junctions. Qualitatively, these data
demonstrate several key points. First, seven of the nine
independently addressable NW/neurite junctions yield reprodu-
cible conductance spikes correlated with IC stimulation. This
density of hybrid NW/neurite synapses on a single cell is
unmatched by previous electrophysiological work.[442,460,469–472]
While previous studies using glassmicroelectrodes have recorded
spike propagation in axons and dendrites,[470,471] axon/dendrite
propagation has not been measured simultaneously nor has the
same level or recording points been achieved (although it has
been demonstrated that measurements can be taken at multiple
points by moving a single pipette probe). Second, the
conductance spikes recorded along the axon by elements
1–5 maintain sharp peak shape and relatively constant peak
amplitude. In contrast, the conductance spikes measured by
elements 6–9 along the dendrite exhibit noticeable broadening
and reduced amplitude.
Signals from the multiple, spatially separated NW/neurite
junctions are recorded simultaneously, and thus enable spike
propagation rates to be quantified in both axons and dendrites.[20]
Signal propagation rates of 0.16m s1 for dendrites and
0.43m s1 for axons were calculated. In trials with different
neurons, Gaussian distributions of 0.15 0.04m s1 and
0.46 0.06 for dendrites and axons respectively were found;
these data are comparable to reported propagation rates
measured by conventional electrophysiological methods.[473,474]
High-sensitivity, ‘‘multi-site’’ electrical recording of neuronal
activity and signal propagation has similarities to optical
methods,[475] which rely on the injection of voltage-sensitive
dyes, but also possesses advantages. For example, one or more of
the NW/neurite junctions can be used as inputs to initiate and/or
modulate signal propagation. As such, the NW device can be
configured so that the middle NW junction can apply a variable
potential input to an axon, while other NWs elements are used to
record temporally resolved spike propagation following IC
stimulation on the same axon. As the input on the control wire
changes from 0 to 0.9 V, the downstream propagation of the signal
can be inhibited and ultimately blocked. These results suggest
that inhibition is localized at a given NW/axon input, and is
consistent with local anodic (hyper) polarization of themembrane
at NW/axon synapses. This polarization inhibits and ultimately
blocks the propagation of action potential spikes.[476–478]
These results show that the NW/neurite junctions can be used
beyond simple recording and stimulation, and enable more
subtle modulation of the spike propagation. It should be possible
to extend this approach to modulation of dendritic signals
at the level of individual dendrites. Continuous or analog control
of the speed and amplitude of propagating signals through NW/
neurite junctions could enhance the understanding of synaptic
processing in neuronal networks, especially considering that
arrays of these artificial synapses could be used to modulate and
simultaneously record signals with high spatial and temporal







3994A complete discussion of NW FETs warrants consideration of
unexplored areas and next steps, which will more clearly reveal
potential advantages and disadvantages of NW-based neural inter-
faces.InthecaseofMEAs, [438,439]planarFETs, [377,427,429,440-448], and
NW FETs,[20] the magnitude of recorded signals is strongly
dependent on cell-substrate junction quality. This factor may in
fact be mitigated in the case of NW devices, since NWs protrude
from the surface of the substrate[20] and can therefore form an
enhanced junction with the membrane. Although there is
considerable evidence that micro- and nanoscale structures
uniquely interact with membranes,[463,464] a rational analysis of
NW geometry, surface functionality, and pitch will be needed to
determine the true nature of coupling in this particular system.
Additionally, the substrate itself plays an important role in
neuronal adhesion and viability, and is an advantage in the case of
NW devices since NWs can be assembled on nearly any type of
substrate, including flexible, biocompatible polymers.[465] NW
devices fabricated on novel substrates could offer unique
interfaces with soft, 3D tissue both in vitro and in vivo, and
might moreover avoid the unwanted immune responses
associated with conventional electrodes,[93-101] but will need to
be studied more carefully for cytotoxicity and biocompatibility in
the context of both cells and tissues. Finally, at the present stage of
development, the primary applicability of NW device arrays will
be as tools for neuroscience on well-defined neurons and brain
slice samples; integration of more complex systems such as
prosthetics will require carefully-engineered arrays and surface
chemistries.5.9. Photoactive Nanostructures for the Neuron Interface
Optical stimulation of neurons is the foundation of vision. At the
same time strong optical activity is very characteristic for
nanostructures, and therefore lends itself to the design of
optoelectronic interface with neural tissues. A recent review
shows that technological capabilities of nanomaterials are
promising for solving many challenges that researchers are
facing in developing artificial retinas and similar devices.[479]
Activation of neurons via photostimulation is also relevant for
standard NEs from the perspective of wireless operation of
implantable devices using small hand-held sources of light.
Despite the promise and importance, the actual amount of
research activity in this area is not very high, probably as a result
of the complexity of techniques and equipment necessary.
Most photoactive nanostructures studied so far can be
described as semiconductor photoactive coatings with thick-
nesses in nanometer scale designed to function as artificial
retinas.[479] These coatings can be both organic[480] or inor-
ganic.[481–485] The most popular organic material for optical
stimulation of neurons is bacteriorhodopsin, while inorganic
coatings are typically made from standard doped silicon or other
semiconductors. By and large, the design of these devices is
identical to solar cells. Similarly to other NEs, flexibility and
mechanical compatibility with the retinal tissue was identified as
one of the most important parameters of the long-term
performance of the device[485] in order to minimize the damage
during ophthalmic surgery and to get better contact to eye
neurons. 2009 WILEY-VCH Verlag GmbMacromolecules and complexes with nanoscale dimensions
for optical stimulation of neurons were also utilized for optical
stimulation of neurons. The purpose of these studies is typically
unrelated to artificial vision; they are motivated primarily by the
search of non-invasive methods for the temporally and spatially
precise activation of neurons. Optical tools become very
convenient for probing neuronal sensitivity, mimicking synaptic
connections, elucidating patterns of neural connectivity, and
unraveling neural circuits in complex neural networks.[486]
Starting from single neurons, one can genetically engineer ion
channels in a neuron to have a photoactivated switch, which
allows the researcher to turn them on and off using light.[487]
Optically gated ion channels can also be produced using a process
dubbed ‘‘genetic chARGing’’ targeting the alpha subunit of the G
protein.[488] When such neurons are generated in the brain of a
live organism, for instance drosophila flies, illumination of the
neurons resulted in complex behaviors, such as jumping, wing
beating, and flight, specific to the functionality of the brain area
where the neuron modification was performed.[489]
Optical stimulation of individual neurons in brain slices in an
arbitrary spatiotemporal pattern was achieved using two-photon
uncaging of 4-methoxy-7-nitroindolinyl-glutamate which equates
to the local photostimulated release of a neurotransmitter. The
advantage of this technique is that it has single-cell and
three-dimensional precision. By sequentially stimulating up to
a thousand potential presynaptic neurons, detailed functional
maps of inputs to a cell were generated.[490] Similar purpose was
behind the use of optical modulation of neuronal activity taking
advantage of a light-driven chloride pump integrated in the
cellular membrane.[491] This system allows either knockout of
single action potentials, or sustained blockade of spiking. When
combined with calcium imaging, light-controlled chloride pumps
produce a system for multimodal, high-speed, genetically
targeted, all-optical interrogation of living neural circuits.[491]
Usefulness of optical control of neural activity can be demon-
strated by the fact that light-induced activation allowed elucida-
tion of the physiological model of depression and other
malfunctions of CNS.[492–494]
Interesting possibilities are provided when semiconductor NP
(quantum dots) are coupled to ion channels. These nanoscale
colloids have a very high optical cross-section and can generate a
large dipole moment around them. When conjugated to cell
membrane in the vicinity of an ionic channel, NPs can potentially
perturb the nerve membrane potentials by blocking ion transport
through it. As a first step, toward this goal, an NP-neuron
interface was made by attaching CdS NPs to neurons.[495] After
that, however multiple challenges were found on the realization
of this goal starting from cytotoxicity of NPs (see Section 3.1) and
non-specific binding to rapid endocytosis of the attached NPs
inside the cell.[479]
One interesting example of quantum-dot based optically active
interface is a hybrid bionanodevice made on the basis of HgTe
NPs. These quantum dots absorb light and stimulate neural cells
following a sequence of photochemical and charge-transfer
reactions.[203] HgTe NP films (Fig. 14A and B), were assembled by
the LBL technique into a tightly packed (Fig. 14B) conductive
composite film. Electrons and holes produced by excitons
photogenerated in quantum-confined HgTe resulted in cathodic







Figure 14. A) Schematics of the photoinduced stimulation of neurons by the layer of NPs.
B) Atomic forcemicroscopy image of the NP layers before adhesion of neurons. C) Kinetics of the
photoinduced current in the NP layer. D) Optical microscopy of the patch clamp contacting the
neuron under investigation. E) Train of the transmembrane potential signals of neuron adhering
to the NP film excited by the train of light pulses. Lower curve: the same signals after addition of
tetrodoxine (TTX). Adapted with permission from [203]. Copyright 2007, ACS.spike (Fig. 14C). The photocurrent originates from the photo-
induced electron transfer from NPs to molecules of oxygen
present in solution. The positive charge at the outer interface of
the film is accumulated due to fairly slow electron transport
through NP solids, which is particularly true for LBL films.[496]
This charge is used to excite differentiated NG108-15 neuron cells
adherent to the NP film, which can be registered with IC
trans-membrane potential measurements with patch clamp
(Fig. 14D). When stimulated with a 532 nm laser, neurons show
depolarization. The LBL method offers the possibility to engineer
the interface and fine-tune neural response in nano-bio devices.
As such, additional LBL films of clay sheets were deposited on top
of the NP films. They imparted greater biocompatibility and
reduced gap between the surface of the device and neural
membrane. Also, clay-polyelectrolyte films increased the dielec-
tric constant and ionic conductivity.[497,498] As a result, depolar-
ization of the cells greatly increased (Fig. 14E) and many of them
demonstrated action potential when depolarization generated a
signal in another neuron. Overall the mechanism of transduction
of optical signal in the neural response can be described as
induction of a large voltage drop across neuronal membrane due
to photocurrents in the NP layers. In response to that, Naþ ion
channels open and the action potential is generated. The
mechanism of the photoinduced stimulation was confirmed
using a potent neurotoxin tetrodoxin, which functions as Naþ ion
channel blocker and dampened the cellular response (Fig. 14E) to
light.
6. Future Perspectives
There is an urgent need for finding therapies to neural disorders
with strategies involving drug delivery, tissue repair, and electricalAdv. Mater. 2009, 21, 3970–4004  2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinimplants. The latter will also greatly benefit
many other diseases treatable by appropriate
electrical stimulation of CNS or peripheral
nerves. These advancements rely on better
diagnostics, therapeutic targets, and ex vivo
modeling of neural tissue as tools for guiding
these strategies. As one can see neural
interfaces represent a very diverse field of
practical applications with challenging require-
ments, which are only partially fulfilled by
current methods and materials. In our
opinion, the future of neural interfaces lies
in the integration of traditional approaches
used so far and nanoscale materials and
devices that can enhance, improve and, in
some cases, revolutionize the current technol-
ogies used to investigate, access, monitor, and
stimulate neural tissues. In this part, we will
present a brief outline of the most fruitful and
important venues of nanotechnology develop-
ment in the next 5–10 years that can address
the needs of neurobiology. In doing so, we do
not intend to predict the future, but rather to
answer the question ‘‘Where one might go
from here?’’ given the state-of-the-art
described in all the sections above.
Since the technology of the NEs is fairly well
developed, new types of coatings that reduce inflammation and
improve survival of neurons in the neural tissue will probably be
the first applications of nanotechnology in this field. Nanoscale
topological features have been shown to increase cell adhesion
and viability (see Sections 5.1–5.5),[362] which may be exploited to
make neuron-device coupling more reliable. Novel substrate
coatings offered by nanomaterials can be used to immobilize cells
and increase the number of cells growing neurites. One very
successful example is peptide nanofibers, which enable rapid
selective neuronal differentiation by amplification of bioactive
epitopes presented to cells.[257] This can certainly be extended
to many NEs. Incorporation of anti-inflammatory
drugs[383,388,499,500] in the coatings and neuronal guidance toward
the electrode by self-assembled scaffolds represent the directions
with greatest immediate and practical importance. The
approaches described in Sections 4.1, 5.2, and 5.4 will make
possible substantial improvement in the performance of NEs.
The combination of neural guidance and drug elution capabilities
in one coating should be strongly considered.
Future development of nanostructured coatings will also target
significant increase of charge injection capacity and reduction of
interface impedance. This task might be achieved by incorpora-
tion of nanoscale features in traditional Ir/IrOx electrodes or
coating metals with other nanomaterials such as CNTs. This
venue is critical for the further miniaturization of the traditional
stimulation electrodes necessary for more selective, ‘‘intelligent’’
excitation of neuronal cells and for the reduction of inflammation
effects by using smaller and more compliant NEs. Drastically
increased improvement of electrical and biological characteristics
of the interface between neuronal cells and NE materials is a
prerequisite for the success of MEAs (see Sections 5.1.2 and







3996dimensions in traditional Michigan electrodes necessary for
reduction of scarring of neural tissue.
Considering the NE challenges outlined in Section 2.3, it might
also be the time to completely rethink the design of an electrode
and to change the existing status quo in NEs. Ideally, a neural
stimulation electrode should be integrated in the tissue as a
compliant flexible material resulting in minimal disturbance to
the tissue. For cuff implants, electrodes must be well integrated
with the thin insulating backing to prevent microscale delamina-
tion of the metal coating.[92] Nanoscale topology and/or coating
with high aspect ratio features on the surface are known to
improve charge injection in neurons,[501–505] and can certainly be
added to it. Considering brain and spinal stimulation, the
electrodes should also be of limited diameter because larger shaft
implants have been shown to activate immune responses in
greater extent.[76,111] Hypothetically speaking, the electrode
should also provide side branches in the form of flexible soft
mesoscale leaflets to reach larger number of cells or other means
to interpenetrate the tissue much better. The leaflet or similar
geometry of the side branches as opposed to more common
fibrous geometry will generate area of contact with the neuronal
cells sufficient for activation. The branches should extend
probably 75–100mm off the main insulated shaft to reach the
greater number of neurons and penetrate through a potential
encapsulation sheath. An NE design incorporating some of these
design ideas not necessarily to the letter but rather mimicking the
structure of neural tissue itself with, for instance, in situ gellation
of conductive SWNTcomposite as a likely implementation of this
approach, will make excitation process more efficient and less
traumatic for the tissue. However, it does imply difficulties with
implantation process, which may require further changes in the
concept of the electrode, while retaining the general function-
alities and design purposes of the newNE as described above. The
questions about control of the quality of interface and its
reproducibility need to be addressed as well, which will likely
require potentially integration of membrane potential contrast
agents in the electrode structure as well.
Manufacturing of this or similar devices, although technically
possible, is limited by the physical properties of the available
materials. Electrical and mechanical properties represent the key
limitations, and should a highly conductive yet mechanically
strong and flexible material becomes available, a new generation
of NEs can be designed and tested. Needless to say, suchmaterials
will also be valuable for other applications in biomedical
engineering and health technologies. Therefore, fundamental
studies on the development of strong, easily manufacturable,
highly conductive materials that can resolve issues with
mechanical properties of NE (see Section 2.3.2) would be quite
important. The development of such materials can go along
several directions, which are likely to include both conductive
polymers,[506] CNT composites,[19,152,200,507] and potentially other
previously unused materials. In this respect, the studies of the
chronic long-term toxicity of such materials over the period of
implantation spanning several years are also very necessary. They
will probably become a bottleneck because they cannot start until
such material and method of manufacturing of electrodes are
identified. As we saw in Section 3.2, the tissue effect is strongly
dependent on method of manufacturing of such composites and
not just on the individual ingredients. 2009 WILEY-VCH Verlag GmbFETs (Section 5.7) as recoding sites do share many challenges
of the common shank and cuff electrodes but do provide an
interesting direction of NE especially if better connectivity with
neuron membrane can be obtained. High sensitivity and gentler
capacitive coupling are the key advantages of this technology.
However, studies on FETs were carried out only in vitro and,
hence, animal studies and design of the chip suitable for such
studies would be most necessary. One of the greatest challenges
here is the maintenance of the small gap between the device and
target cell because the device performance is critically dependent
on it. Coatings and nanostructured surfaces can significantly
contribute toward defeating this challenge. Also, a ‘‘soft’’
nanoscale FET that can reside on the cell surface will integrate
very well with the outline of the new generation of NE described
above. Therefore, highly flexible FETs compliant with neural
tissues should be developed. Without this step, their utility will be
limited due to inflammatory reactions. The flexible FETs are likely
to need new semiconducting and insulating media because
traditional Si/SiO2 chips are fairly hard and brittle.
The new generation of FETs from NWs (Section 5.8) may be
used to dramatically increase the resolution of detection and
stimulation of neuronal activity.[20] One of the advantages of NW
FETs is the ability to readily integrate distinct materials, such as n-
and p-type NWs, and hence, low-power logic gates, followers, and
amplifiers, that are ubiquitous inmicroelectronics, and have been
interfaced with whole cells as planar FETs.[462] This opens up
future opportunities for on-NE processing elements, new means
of interfacing,[508,509] and recording/excitation of cellular signals
from multiple sites.[510,511] This function will also be helpful for
establishing the mechanisms of therapeutic actions of DBS,[512]
which are currently quite obscure (see Section 2.3.5) and
represents one of the important challenges of the field.
Classical planar and NW FETs share some of these exciting
opportunities, and in particular could satisfy one of the acute
needs of basic research. Configuring FETs to behave as chemical
sensors could enable one to correlate neurotransmitter release to
electronic signaling for NW[513,514] and planar FETs[17,515–517] with
individual nanodevices in an array being designed, through
specific chemical interactions or modulation of applied redox
potentials, to simultaneously detect a matrix of biologically
significant species. Special attention here should probably be
given to FETs from CNTs using special properties of NT
composites[16,518] and/or taking advantage of new types of
electronic devices possible from these nanoscale building blocks
such as ballistic FETs[519] or ultrasensitive capacitors.[520] FETs
from CNTs have an excellent track record, but have never been
used in neural applications.[521–523]
More NEs should be made incorporating light-sensitive
materials for light-addressable interfaces,[203] which is likely to
be one of the most promising directions for the future
development of light-sensitive interfaces. Note though, that
mechanical properties and miniaturization of active electrode
surfaces acquire probably even greater importance when
photoactive NEs are designed to serve as an artificial retina.
The presence of photoreactions at the interface gives additional
restrictions on the materials to be used, their biocompatibility,
and long-term stability. As such, many dyes adsorbing in visible
light including previously used bacteriorhodopsin are also subject






www.advmat.dea long time. More stable inorganic semiconductor materials that
are active in the visible spectrum tend to contain heavy metals,
which are likely to cause problems with long-term biocompat-
ibility. Hence finding and testing alternate nanostructured
materials and potentially differently doped inorganic nanocol-
loids should be charted as one of the future tasks in this area.
As well, photoreactions often generate free radicals including
ROS, which are found to initiate neural damage. They certainly
need to be minimized and mitigated. Fullerene coatings (see
Section 4.1.2) can serve as an intermediate solution for this
offering both strong photovoltaic activity in the visible range and
radical savaging. CNTs may also give adequate performance and
can possibly surpass other materials as a potential candidate for
an artificial retina. However, their adsorption spectrum tends to
include IR bands and thus may result in greater sensitivity to IR
emission, which may not be a disadvantage. Besides artificial
retinas, this property could also be used for remote electrodeless
excitation of implanted NE. Human tissues have a window of
transparency in near IR. In perspective, it is possible to design a
photosensitive cuff electrode that can be positioned around a
nerve and stimulated by a small red laser similar to classroom
pointer.
Nanoscale materials for neural interfaces are also associated
with systemic drug delivery and imaging using organic and
inorganic NPs (see Sections 4.1.1 and 4.2). These tasks are
particularly significant for the diagnostics and treatment of brain
cancers and malfunctions of other parts of CNS. Although much
(see Section 4.2) work had been done, this is still a challenging
problem. Detailed understanding of the regularities and
tendencies that govern the permeation of NPs through the
BBB in respect to size, charge, and surface functionalities and
subsequent maximization of this function is one of the important
future targets in this area. The addition of therapeutic functions,
for instance drug delivery, and imaging capabilities on top of BBB
transparency will lead to a new generation of treatment methods
for brain tumors. This will be particularly advantageous for early
stages of tumors when vasculature has not developed the
characteristic leaks and become more permeable. Although
magnetic NPs have been FDA approved and used since 1980s,
detailed understanding of their transport to neural tissues and the
degree of its external positioning control in humans is still
needed.
More generally, we believe that nanotechnology can also
strongly impact in vitro drug assays[66] necessary for the treatment
of neurodegenerative disorders, neural restoration, inflamma-
tions in CNS and peripheral nervous system, and psychological
deceases. As an example, the scalable nature and biocompatibility
of FET, especially NW FETs, devices lends them to new methods
of drug selection with much increased rate and accuracy of
screening. One of the interesting challenges in this area is
switching from the traditional screening in 2D plates to 3D
scaffolds since neurons have extensive volumetric interconnec-
tions critically relevant to their performance that are distorted in
2D systems. Finding substrates for 3D drug screening will likely
require the combination of both nanoscale and microscale
features of the material.[524,525]
Last but not least, we also would like to address the use of stem
cells in combination with the materials discussed above. The
discovery of NSC in adult brains has a crucial significance, in ourAdv. Mater. 2009, 21, 3970–4004  2009 WILEY-VCH Verlag Gopinion, for neural interfaces. Yet very little work is being done in
this area and only very recently.[387] NSCs have the ability to
transform into functional neurons[526,527] and integration of
NSCs with the electrode can simplify its implantation, increase
the number of neurons in actual contact with the NE, and create a
living interface with the surrounding tissue. It is envisioned that
NSCs will differentiate once implanted, develop processes
penetrating through the encapsulating layer, and form natural
biological connections to the surrounding neurons. The fact that
NSCs can create functional signal-bearing networks similar to
normal neurons has already been demonstrated.[528] Importantly,
NSCs can also be developed from hematopoietic CD34-positive
stem cells from peripheral blood of adults,[529–533] therefore,
making possible the development of the interface with the
patient’s own stem cells. This will greatly reduce or possibly
completely eliminate the immune response of the nervous tissue
and can resolve many challenges outlined above.Acknowledgements
Thanks are due to Prof. Andreas Offenhauzer, Prof. Adam Curtis,
Dr. Allison Beattie, Prof. Matis Riehle, and Prof. Chris Wilkinson for useful
textual contribution to the review, which were partially incorporated in the
manuscript in Section 5.2.2. Stimulating discussions, clarifications, and
insights of Profs. Ken Wise, Khalil Najafi, Daryl Kipke, David Martin were
also greatly appreciated.
Received: July 13, 2008
Revised: January 1, 2009
Published online: July 8, 2009[1] D. F. Emerich, C. Halberstadt, C. Thanos, J. Biomed. Nanotechnol. 2007, 3,
235.
[2] K. K. Jain, Clin. Chem. 2007, 53, 2002.
[3] K. K. Jain, Neurodegener. Dis. 2007, 4, 287.
[4] R. S. Kane, A. D. Stroock, Biotechnol. Prog. 2007, 23, 316.
[5] K. Najafi, Handbook of Microlithography, Micromachining, and Microfabri-
cation, SPIE-International Society for Optical Engine, Chicago 1997, p. 517.
[6] D. Banks, Eng. Sci. Educ. J. 1998, 7, 135.
[7] P. Heiduschka, S. Thanos, Prog. Neurobiol. 1998, 55, 433.
[8] T. Stieglitz, J.-U. Meyer, in Microsystem Technology in Chemistry and Life
Science (Eds: A. Manz, H. Becker), Springer, Berlin 1998, 131.
[9] J. P. Donoghue, Nat. Neurosci. 2002, 5, 1085.
[10] K. D. Wise, IEEE Eng. Med. Biol. Magazine 2005, 24, 22.
[11] T. M. Pearce, J. C. Williams, Lab Chip 2007, 7, 30.
[12] G. A. Silva, Nat. Rev. Neurosci. 2006, 7, 65.
[13] J. M. Koziara, P. R. Lockman, D. D. Allen, R. Mumper, J. Pharm. Res. 2003,
20, 1772.
[14] P. Yao, J. Huang, C. Kang, P. Pu, J. Chang, Zhongguo Yixue Kexueyuan
Xuebao 2006, 28, 481.
[15] A. Bianco, K. Kostarelos, C. D. Partidos, M. Prato, Chem. Comm. 2005,
571.
[16] M. K. Gheith, T. C. Pappas, A. V. Liopo, V. A. Sinani, B. S. Shim, M.
Motamedi, J. P. Wicksted, N. A. Kotov, Adv. Mater. 2006, 18, 2975.
[17] L. Wang, D. Fine, D. Sharma, L. Torsi, A. Dodabalapur, Anal. Bioanal.
Chem. 2006, 384, 310.
[18] T. J. Webster, M. C. Waid, J. L. McKenzie, R. L. Price, J. U. Ejiofor,







3998[19] M. K. Gheith, V. A. Sinani, J. P. Wicksted, R. L. Matts, N. A. Kotov, Adv.
Mater. 2005, 17, 2663.
[20] F. Patolsky, B. P. Timko, G. Yu, Y. Fang, A. B. Greytak, G. Zheng, C. M.
Lieber, Science 2006, 313, 1100.
[21] G. Ruan, A. Agrawal, A. M. Smith, X. Gao, S. Nie, Rev. Fluoresc. 2006, 3,
181.
[22] M. R. Warnement, I. D. Tomlinson, S. J. Rosenthal, Curr. Nanosci. 2007, 3,
273.
[23] K. T. Thurn, E. M. B. Brown, A. Wu, S. Vogt, B. Lai, J. Maser, T. Paunesku,
G. E. Woloschak, Nanoscale Res. Lett. 2007, 2, 430.
[24] K. Khosravi-Darani, A. Pardakhty, H. Honarpisheh, V. S. N. M. Rao, M. R.
Mozafari, Micron 2007, 38, 804.
[25] W. Cai, A. R. Hsu, Z.-B. Li, X. Chen, Nanoscale Res. Lett. 2007, 2, 265.
[26] H. M. E. Azzazy, M. M. H. Mansour, S. C. Kazmierczak, Clin. Biochem.
2007, 40, 917.
[27] W. Jiang, A. Singhal, H. Fischer, S. Mardyani, W. C. W. Chan, BioMEMS
Biomed. Nanotechnol. 2006, 3, 137.
[28] I. L. Medintz, H. T. Uyeda, E. R. Goldman, H. Mattoussi,Nat. Mater. 2005,
4, 435.
[29] J. L. West, N. J. Halas, Annu. Rev. Biomed. Eng. 2003, 5, 285.
[30] J. E. Jensen, R. R. Conn, G. Hazelrigg, J. E. Hewett, Am. J. Sports Med.
1985, 13, 27.
[31] A. H. Gordon, C. W. Schwabe, The Quick and the Dead: Biomedical Theory
in Ancient Egypt, Brill Academic Publishers, Leiden, The Netherlands
2004.
[32] P. L. Gildenberg, Pain Med. 2006, 7, S7.
[33] W. L. C. Rutten, Annu. Rev. Biomed. Eng. 2002, 4, 407.
[34] R. A. Normann, Nat. Clin. Pract. Neuro. 2007, 3, 444.
[35] L. Galvani, De Bononiensi Scientarium et Artium Instituto adque Academia
Commentarii 1791(7), 363.
[36] M. Pruel, in: A History of Neurosurgery (Eds: S, Greenblatt, T, Dagitf, M.
Epstein ), American Association of Neurological Surgeons, Park Ridge, IL
1997, p. 99.
[37] W. Isaacson, Benjamin Franklin: An American Life, Simon & Schuster, New
York 2003.
[38] B. Franklin, Phil. Trans. Roy. Soc. 1758(50), 481.
[39] A. L. Hodgkin, A. F. Huxley, Nature 1939, 144, 710.
[40] C. A. Terzuolo, T. Araki, Ann. N. Y. Acad. Sci. 1963, 94, 547.
[41] M. Verseano, K. Negishi, J. Gen. Physiol. 1960, 43, 177.
[42] F. A. Spelman, IEEE Eng. Med. Biol. Magazine 1999, 18, 27.
[43] K. D. Wise, J. B. Angell, A. Starr, IEEE Trans. Biomed. Eng. 1970, BME-17,
238.
[44] K. D. Wise, J. B. Angell, IEEE Trans. Biomed. Eng. 1975, BME-22, 212.
[45] K. Jones, P. Campbell, R. Normann, Ann. Biomed. Eng. 1992, 20, 423.
[46] K. Bradley, Pain Med. 2006, 7, S27.
[47] D. Harnack, C. Winter, W. Meissner, T. Reum, A. Kupsch, R. Morgenstern,
J. Neurosci. Meth. 2004, 138, 207.
[48] J. M. Kerns, A. J. Fakhouri, H. P. Weinrib, J. A. Freeman,Neuroscience 1991,
40, 93.
[49] D. R. Merrill, M. Bikson, J. G. R. Jefferys, J. Neurosci. Meth. 2005, 141, 171.
[50] A. L. Benabid, Curr. Opin. Neurobiol. 2003, 13, 696.
[51] M. A. Lebedev, M. A. L. Nicolelis, Trends Neurosci. 2006, 29, 536.
[52] R. R. Llinas, K. D. Walton, M. Nakao, I. Hunter, P. A. Anquetil,
J. Nanoparticle Res. 2005, 7, 111.
[53] F. A. Mussa-Ivaldi, L. E. Miller, Trends Neurosci. 2003, 26, 329.
[54] F. A. Spelman, Audiol. Neurootol. 2006, 11, 77.
[55] a) P. L. Marzella, G. M. Clark, Acta Otolaryngol. 1999, 119, 407; b) X.
Navarro, T. B. Krueger, N. Lago, S. Micera, T. Stieglitz, P. Dario, J. Periph.
Nerv. Syst. 2005, 10, 229.
[56] G. Schalk, J. Neural Eng. 2008, 5, P1.
[57] C. Haberler, F. Alesch, P. R. Mazal, P. Pilz, K. Jellinger, M. M. Pinter, J. A.
Hainfellner, H. Budka, Ann. Neurol. 2000, 48, 372.
[58] J. L. Vitek, T. Hashimoto, J. Peoples, M. R. DeLong, R. A. E. Bakay,
Movement Disord. 2004, 19, 907. 2009 WILEY-VCH Verlag Gmb[59] J.-Y. Chang, J. Pharmacol. Exp. Ther. 2004, 309, 1.
[60] C. Hamani, M. P. McAndrews, M. Cohn, M. Oh, D. Zumsteg, C. M.
Shapiro, R. A. Wennberg, A. M. Lozano, Ann. Neurol. 2008, 63, 119.
[61] M. W. Keith, Microsurgery 2001, 21, 256.
[62] K. E. Matzel, U. Stadelmaier, M. Hohenfellner, W. Hohenberger, Dis.
Colon Rectum 2001, 44, 59.
[63] J. Rozman, B. Zorko, M. Bunc, M. Zitko, Artif. Organs 2002, 26, 241.
[64] J. Andrews Russell, Ann. N. Y. Acad. Sci. 2003, 993, 1.
[65] P. J. Goodnick, A. J. Rush, M. S. George, L. B. Marangell, H. A. Sackeim,
Expert Opin. Pharmacother. 2001, 2, 1061.
[66] E. H. Paul, III, B. N. Charles, Expert Opin. Pharmacother. 2006, 7,
2323.
[67] T. Matsumoto, T. Kanno, Peptides 1984, 5, 285.
[68] O. E. Osadchii, V. M. Pokrovskii, O. G. Kompaniets, A. N. Kurzanov, Bull.
Exp. Biol. Med. 1997, 123, 427.
[69] M. Yamazaki, T. Sakaguchi, Brain Res. 1989, 484, 357.
[70] A. Yoshizaki, Y. Takagi, T. Kanno, Biomed. Res. 1992, 13, 303.
[71] N. I. Ziyatdinova, A. A. Gainullin, A. U. Ziganshin, T. L. Zefirov, Bull. Exp.
Biol. Med. 2004, 137, 425.
[72] T. Stieglitz, J.-U. Meyer, Microsystems 2007, 16, 41.
[73] J. Gimsa, B. Habel, U. Schreiber, U. V. Rienen, U. Strauss, U. Gimsa,
J. Neurosci. Meth. 2005, 142, 251.
[74] D. B. McCreery, W. F. Agnew, T. G. H. Yuen, L. Bullara, IEEE Trans. Biomed.
Eng. 1990, 37, 996.
[75] R. D. Foreman, B. Linderoth, J. L. Ardell, K. W. Barron, M. J. Chandler, S. S.
Hull, G. J. TerHorst, M. J. L. DeJongste, J. A. Armour, Cardiovasc. Res.
2000, 47, 367.
[76] L. C. R. Wim, Annu. Rev. Biomed. Eng. 2002, 4, 407.
[77] B. Coburn, Crit. Rev. Biomed. Eng. 1989, 17, 133.
[78] F. Rattay, Neuroscience 1999, 89, 335.
[79] C. C. McIntyre, M. Savasta, L. K.-L. Goff, J. L. Vitek, Clin. Neurophysiol.
2004, 115, 1239.
[80] E. J. Tehovnik, A. S. Tolias, F. Sultan, W. M. Slocum, N. K. Logothetis,
J. Neurophysiol. 2006, 96, 512.
[81] S. R. F. Rattay, P. Lutter, K. Minassian, B. Jilge, M. R. Dimitrijevic,
Neuromodulation 2003, 6, 42.
[82] B. Wessling, A. Besmehn, W. Mokwa, U. Schnakenberg, J. Electrochem.
Soc. 2007, 154, F83.
[83] E. Slavcheva, R. Vitushinsky, W. Mokwa, U. Schnakenberg, J. Electrochem.
Soc. 2004, 151, E226.
[84] I.-S. Lee, C.-N. Whang, J.-C. Park, D.-H. Lee, W.-S. Seo, Biomaterials 2003,
24, 2225.
[85] T. M. Silva, J. Rito, M. G. S. Ferreira, I. Fonseca, K. Watkins, J. Mater. Sci.:
Mater. Med. 1996, 7, 261.
[86] S. F. Cogan, A. A. Guzelian, W. F. Agnew, T. G. H. Yuen, D. B. McCreery,
J. Neurosci. Meth. 2004, 137, 141.
[87] M. HajjHassan, V. Chodavarapu, S. Musallam, Sensors 2008, 8, 6704.
[88] P. J. Rousche, D. S. Pellinen, D. P. Pivin, Jr, J. C. Williams, R. J. Vetter, D. R.
Kipke, IEEE Trans. Biomed. Eng. 2001, 48, 361.
[89] A. J. Engler, S. Sen, H. L. Sweeney, D. E. Discher, Cell. 2006, 126, 677.
[90] D. E. Discher, P. Janmey, Y-l. Wang, Science 2005, 310, 1139.
[91] H. Specht, F. Krueger, H. J. Wachter, O. Keitel, C. Leitold, M. Frericks,Med.
Device Mater. III, Proc. 3rd Mater. Processes Med. Devices Conf. 2006,
p. 169.
[92] U. M. Twardoch, J. Appl. Electrochem. 1994, 24, 835.
[93] J. N. Turner, W. Shain, D. H. Szarowski, M. Andersen, S. Martins, M.
Isaacson, H. Craighead, Exp. Neurol. 1999, 156, 33.
[94] D. H. Szarowski, M. D. Andersen, S. Retterer, A. J. Spence, M. Isaacson,
H. G. Craighead, J. N. Turner, W. Shain, Brain Res. 2003, 983, 23.
[95] Y.-T. Kim, R. W. Hitchcock, M. J. Bridge, P. A. Tresco, Biomaterials 2004,
25, 2229.
[96] R. Biran, D. C. Martin, P. A. Tresco, Exp. Neurol. 2005, 195, 115.
[97] D. J. Edell, V. V. Toi, V. M. McNeil, L. D. Clark, IEEE Trans. Biomed. Eng.






www.advmat.de[98] S. J. A. Davies, M. T. Fitch, S. P. Memberg, A. K. Hall, G. Raisman, J. Silver,
Nature 1997, 390, 680.
[99] R. W. Griffith, D. R. Humphrey, Neurosci. Lett. 2006, 406, 81.
[100] R. Griffith, J. Soria, J. G. Wood, Exp. Neurol. 2000, 161, 297.
[101] J. W. Fawcett, R. A. Asher, Brain Res. Bull. 1999, 49, 377.
[102] A. M. P. Turner, N. Dowell, S. W. P. Turner, L. Kam, M. Isaacson, J. N.
Turner, H. G. Craighead, W. Shain, J. Biomed. Mater. Res. 2000, 51,
430.
[103] P. M. St, John, L. Kam, S. W. Turner, H. G. Craighead, M. Issacson, J. N.
Turner, W. Shain, J. Neurosci. Meth. 1997, 75, 171.
[104] J. Subbaroyan, C. Martin David, R. Kipke Daryl, J. Neural Eng. 2005, 2, 103.
[105] H. Lee, R. V. Bellamkonda, W. Sun, M. E. Levenston, J. Neural Eng. 2005,
2, 81.
[106] A. Gilletti, J. Muthuswamy, J. Neural Eng. 2006, 3, 189.
[107] G. C. McConnell, T. M. Schneider, J. Owens, R. V. Bellamkonda, IEEE
Trans. Biomed. Eng. 2007, 54, 1.
[108] R. Biran, D. C.Martin, P. A. Tresco, J. Biomed. Mater. Res, Part A 2007, 82A,
169.
[109] Y. T. Kim, R. W. Hitchcock, M. J. Bridge, P. A. Tresco, Biomaterials 2004,
25, 2229.
[110] E. A. Nunamaker, E. K. Purcell, D. R. Kipke, J. Biomed. Mater. Res, Part A
2007, 83A, 1128.
[111] J. P. Seymour, D. R. Kipke, Biomaterials 2007, 28, 3594.
[112] F. Keohan, X. F. Wei, A. Wongsarnpigoon, E. Lazaro, J. E. Darga, W. M.
Grill, J. Biomater. Sci, Polym. Ed. 2007, 18, 1057.
[113] C. S. Bjornsson, S. J. Oh, Y. A. Al-Kofahi, Y. J. Lim, K. L. Smith, J. N. Turner,
S. De, B. Roysam, W. Shain, S. J. Kim, J. Neural Eng. 2006, 3, 196.
[114] V. S. Polikov, P. A. Tresco, W. M. Reichert, J. Neurosci. Meth. 2005, 148, 1.
[115] A. W. Unterberg, J. Stover, B. Kress, K. L. Kiening, Neuroscience 2004, 129,
1021.
[116] M. T. Fitch, J. Silver, Exp. Neurol. 1997, 148, 587.
[117] S. F. Bernatchez, P. J. Parks, D. F. Gibbons, Biomaterials 1996, 17, 2077.
[118] J. E. Sanders, C. E. Stiles, C. L. Hayes, J. Biomed. Mater. Res. 2000, 52, 231.
[119] C. S. Chen, J. Tan, J. Tien, Annu. Rev. Biomed. Eng. 2004, 6, 275.
[120] C. S. Chen, M. Mrksich, S. Huang, G. M. Whitesides, D. E. Ingber, Science
1997, 276, 1425.
[121] Y.-T. Kim, V. K. Haftel, S. Kumar, R. V. Bellamkonda, Biomaterials 2008, 29,
3117.
[122] L. Bekar, W. Libionka, G.-F. Tian, Q. Xu, A. Torres, X. Wang, D. Lovatt, E.
Williams, T. Takano, J. Schnermann, R. Bakos, M. Nedergaard, Nat. Med.
2008, 14, 75.
[123] M. L. Kringelbach, N. Jenkinson, S. L. F. Owen, T. Z. Aziz, Nat. Rev.
Neurosci. 2007, 8, 623.
[124] J. T. Moyer, S. F. Danish, J. Neurosci. 2007, 27, 1799.
[125] J. S. Perlmutter, J. W. Mink, Annu. Rev. Neurosci. 2006, 29, 229.
[126] J. L. Vitek, Mov. Disord. 2002, 17, S69.
[127] J. O. Dostrovsky, R. Levry, J. P. Wu, W. D. Hutchison, R. R. Tasker, A. M.
Lozano, J. Neurophysiol. 2000, 84, 570.
[128] C. Beurrier, B. Bioulac, J. Audin, C. Hammond, J. Neurophysiol. 2001, 85,
1351.
[129] C. B. McCracken, A. A. Grace, J. Neurosci. 2007, 27, 12601.
[130] G. Peleg, A. Lewis, M. Linial, L. M. Loew, Proc. Natl. Acad. Sci. USA 1999,
96, 6700.
[131] J. A. Kloepfer, N. Cohen, J. L. Nadeau, J. Phys. Chem. B 2004, 108, 17042.
[132] V. Salnikov, Y. O. Lukyanenko, C. A. Frederick, W. J. Lederer, V. Lukya-
nenko, Biophys. J. 2007, 92, 1058.
[133] J. Winter, C. Schmidt, B. Korgel, Optimization of quantum dot—Nerve
cell interfaces, presented at Symposium on Quantum Dots, Nanoparticles
and Nanowires held at the 2003 MRS Fall Meeting, Boston, MA, December
01–05, 2003.
[134] V. Nechyporuk-Zloy, C. Stock, H. Schillers, H. Oberleithner, A. Schwab,
Am. J. Physiol. Cell Physiol. 2006, 291, C266.
[135] S. Ramachandran, N. E. Merrill, R. H. Blick, D. W. V. D. Weide, Biosens.
Bioelectron. 2005, 20, 2173.Adv. Mater. 2009, 21, 3970–4004  2009 WILEY-VCH Verlag G[136] J. L. Nadeau, S. J. Clarke, C. A. Hollmann, D. M. Bahcheli, IEEE, Quantum
dot-FRET systems for imaging of neuronal action potentials, presented at
28th Annual International Conference of the IEEE-Engineering-
in-Medicine-and-Biology-Society, New York, NY, August
30–September 03, 2006.
[137] G. Oberdorster, E. Oberdorster, J. Oberdorster, Environ. Health Perspect.
2005, 113, 823.
[138] E. Oberdorster, Environ. Health Perspect. 2004, 112, 1058.
[139] C. Kirchner, T. Liedl, S. Kudera, T. Pellegrino, A. Munoz Javier, H. E. Gaub,
S. Stolzle, N. Fertig, W. J. Parak, Nano Lett. 2005, 5, 331.
[140] S. Clarke, J. Nadeau, D. Bahcheli, Z. Zhang, C. Hollmann, Conf. Proc. IEEE
Eng. Med. Biol. Soc. 2005, 1, 504.
[141] J. Lovric, S. J. Cho, F. M. Winnik, D. Maysinger, Chem. Biol. 2005, 12, 1227.
[142] A. M. Derfus, W. C. W. Chan, S. N. Bhatia, Nano Lett. 2004, 4, 11.
[143] A. A. Shvedova, V. Castranova, E. R. Kisin, D. Schwegler-Berry, A. R.
Murray, V. Z. Gandelsman, A. Maynard, P. Baron, J. Toxicol. Environ.
Health A 2003, 66, 1909.
[144] C. W. Lam, J. T. James, R. McCluskey, R. L. Hunter, Toxicol. Sci. 2004, 77,
126.
[145] D. B. Warheit, B. R. Laurence, K. L. Reed, D. H. Roach, G. A. Reynolds,
T. R. Webb, Toxicol. Sci. 2004, 77, 117.
[146] N. W. Shi Kam, T. C. Jessop, P. A. Wender, H. Dai, J. Am. Chem. Soc. 2004,
126, 6850.
[147] Y. Sato, A. Yokoyama, K. Shibata, Y. Akimoto, S. Ogino, Y. Nodasaka, T.
Kohgo, K. Tamura, T. Akasaka, M. Uo, K. Motomiya, B. Jeyadevan, M.
Ishiguro, R. Hatakeyama, F. Watari, K. Tohji, Mol. Biosyst. 2005, 1, 176.
[148] D. Cui, F. Tian, C. S. Ozkan, M. Wang, H. Gao, Toxicol. Lett. 2005, 155, 73.
[149] S. K. Manna, S. Sarkar, J. Barr, K. Wise, E. V. Barrera, O. Jejelowo, A. C.
Rice-Ficht, G. T. Ramesh, Nano Lett. 2005, 5, 1676.
[150] C. M. Sayes, F. Liang, J. L. Hudson, J. Mendez, W. Guo, J. M. Beach, V. C.
Moore, C. D. Doyle, J. L. West, W. E. Billups, K. D. Ausman, V. L. Colvin,
Toxicol. Lett. 2006, 161, 135.
[151] M. P. Mattson, R. C. Haddon, A. M. Rao, J. Mol. Neurosci. 2000, 14, 175.
[152] V. Lovat, D. Pantarotto, L. Lagostena, B. Cacciari, M. Grandolfo, M. Righi,
G. Spalluto, M. Prato, L. Ballerini, Nano Lett. 2005, 5, 1107.
[153] M. A. Correa-Duarte, N. Wagner, J. Rojas-Chapana, C. Morsczeck, M.
Thie, M. Giersig, Nano Lett. 2004, 4, 2233.
[154] J. A. Rojas-Chapana, M. Giersig, J. Nanosci. Nanotechnol. 2006, 6, 316.
[155] B. Diaz, C. Sanchez-Espinel, M. Arruebo, J. Faro, E. de Miguel, S.
Magadan, C. Yague, R. Fernandez-Pacheco, M. R. Ibarra, J. Santamaria,
A. Gonzalez-Fernandez, Small 2008, 4, 2025.
[156] N. G. Bastus, E. Casals, S. Vazquez-Campos, V. Puntes, Nanotoxicology
2008, 2, 99.
[157] M. J. D. Clift, B. Rothen-Rutishauser, D. M. Brown, R. Duffin, K. Donald-
son, L. Proudfoot, K. Guy, V. Stone, Toxicol. Appl. Pharmacol. 2008, 232,
418.
[158] C. M. Sayes, A. M. Gobin, K. D. Ausman, J. Mendez, J. L. West, V. L.
Colvin, Biomaterials 2005, 26, 7587.
[159] L. H. Ding, J. Stilwell, T. T. Zhang, O. Elboudwarej, H. J. Jiang, J. P. Selegue,
P. A. Cooke, J. W. Gray, F. Q. F. Chen, Nano Lett. 2005, 5, 2448.
[160] J. R. Gurr, A. S. S. Wang, C. H. Chen, K. Y. Jan, Toxicology 2005, 213, 66.
[161] W. S. Lin, Y. W. Huang, X. D. Zhou, Y. F. Ma, Toxicol. Appl. Pharmacol.
2006, 217, 252.
[162] C. Buzea, I. I. Pacheco, K. Robbie, Biointerphases 2007, 2, MR17.
[163] H. C. Fischer, W. C. W. Chan, Curr. Opin. Biotechnol. 2007, 18,
565.
[164] M. A. Dobrovolskaia, S. E. McNeil, Nat. Nano 2007, 2, 469.
[165] R. Duncan, L. Izzo, Adv. Drug Deliv. Rev. 2005, 57, 2215.
[166] S. Dokka, D. Toledo, X. G. Shi, V. Castranova, Y. Rojanasakul, Pharm. Res.
2000, 17, 521.
[167] H. L. Wong, A. M. Rauth, R. Bendayan, J. L. Manias, M. Ramaswamy, Z. S.
Liu, S. Z. Erhan, X. Y. Wu, Pharm. Res. 2006, 23, 1574.
[168] R. FernandezUrrusuno, E. Fattal, J. M. Rodrigues, J. Feger, P. Bedossa, P.







4000[169] B. Heurtault, P. Saulnier, B. Pech, J. E. Proust, J. P. Benoit, Biomaterials
2003, 24, 4283.
[170] J. Lovric, H. S. Bazzi, Y. Cuie, G. R. Fortin, F. M. Winnik, D. Maysinger,
J. Mol. Med. 2005, 83, 377.
[171] W. H. Chan, N. H. Shiao, P. Z. Lu, Toxicol. Lett. 2006, 167, 191.
[172] A. O. Choi, S. J. Cho, J. Desbarats, J. Lovric, D. Maysinger, J. Nanobio-
technol. 2007, 5, 1.
[173] D.Maysinger, M. Behrendt, M. Lalancette-Hebert, J. Kriz,Nano Lett. 2007,
7, 2513.
[174] T. Q. Vu, R. Maddipati, T. A. Blute, B. J. Nehilla, L. Nusblat, T. A. Desai,
Nano Lett. 2005, 5, 603.
[175] M. P. Waalkes, Mutat. Res. 2003, 533, 107.
[176] A. Hartwig, T. Schwerdtle, Toxicol. Lett. 2002, 127, 47.
[177] G. S. Shukla, R. S. Srivastava, S. V. Chandra, Fundam. Appl. Toxicol. 1988,
11, 229.
[178] A. O. Choi, S. E. Brown, M. Szyf, D. Maysinger, J. Mol. Med. 2007, 86, 291.
[179] T. Zhang, J. L. Stilwell, D. Gerion, L. Ding, O. Elboudwarej, P. A. Cooke,
J. W. Gray, A. P. Alivisatos, F. F. Chen, Nano Lett. 2006, 6, 800.
[180] E. Jan, S. J. Byrne, M. Cuddihy, A. M. Davies, Y. Volkov, Y. K. Gun’ko,
N. A. Kotov, ACS Nano 2008, 2, 928.
[181] S. J. Cho, D. Maysinger, M. Jain, B. Roder, S. Hackbarth, F. M. Winnik,
Langmuir 2007, 23, 1974.
[182] A. C. Samia, X. Chen, C. Burda, J. Am. Chem. Soc. 2003, 125, 15736.
[183] V. A. Sinani, D. S. Koktysh, B.-G. Yun, R. L. Matts, T. C. Pappas, M.
Motamedi, S. T. Thomas, N. A. Kotov, Nano Lett. 2003, 3, 1177.
[184] A. Hoshino, K. Fujioka, T. Oku, M. Suga, Y. F. Sasaki, T. Ohta, M.
Yasuhara, K. Suzuki, K. Yamamoto, Nano Lett. 2004, 4, 2163.
[185] A. Hoshino, N. Manabe, K. Fujioka, K. Suzuki, M. Yasuhara, K.
Yamamoto, J. Artif. Organs 2007, 10, 149.
[186] A. Shiohara, A. Hoshino, K. Hanaki, K. Suzuki, K. Yamamoto, Microbiol.
Immunol. 2004, 48, 669.
[187] M. L. Schipper, N. Nakayama-Ratchford, C. R. Davis, N. W. S. Kam, P.
Chu, Z. Liu, X. Sun, H. Dai, S. S. Gambhir,Nat. Nanotechnol. 2008, 3, 216.
[188] W. Yang, P. Thordarson, J. J. Gooding, S. P. Ringer, F. Braet, Nanotechnol-
ogy 2007, 18, 412001/1.
[189] G. Angelini, S. Boncompagni, P. De Maria, M. De Nardi, A. Fontana, C.
Gasbarri, E. Menna, Carbon 2007, 45, 2479.
[190] M. Prato, K. Kostarelos, A. Bianco, Acc. Chem. Res. 2008, 41, 60.
[191] J. Guo, X. Zhang, Q. Li, W. Li, Nucl. Med. Biol. 2007, 34, 579.
[192] Y. Sato, A. Yokoyama, K.-I. Shibata, F. Watari, K. Tohji, Tanso 2006, 225,
364.
[193] J. M. Ashcroft, K. B. Hartman, Y. Mackeyev, C. Hofmann, S. Pheasant,
L. B. Alemany, L. J. Wilson, Nanotechnology 2006, 17, 5033.
[194] J. C. Carrero-Sanchez, A. L. Elias, R. Mancilla, G. Arrellin, H. Terrones, J. P.
Laclette, M. Terrones, Nano Lett. 2006, 6, 1609.
[195] N. W. S. Kam, Z. Liu, H. Dai, Angew. Chem. Int. Ed. 2006, 45, 577.
[196] N. W. S. Kam, Z. Liu, H. Dai, J. Am. Chem. Soc. 2005, 127, 12492.
[197] H. Dumortier, S. Lacotte, G. Pastorin, R. Marega, W. Wu, D. Bonifazi, J.-P.
Briand, M. Prato, S. Muller, A. Bianco, Nano Lett. 2006, 6, 3003.
[198] V. E. Kagan, Y. Y. Tyurina, V. A. Tyurin, N. V. Konduru, A. I. Potapovich,
A. N. Osipov, E. R. Kisin, D. Schwegler-Berry, R. Mercer, V. Castranova,
A. A. Shvedova, Toxicol. Lett. 2006, 165, 88.
[199] A. Magrez, S. Kasas, V. Salicio, N. Pasquier, J. W. Seo, M. Celio, S.
Catsicas, B. Schwaller, L. Forro, Nano Lett. 2006, 6, 1121.
[200] H. Hu, Y. Ni, V. Montana, R. C. Haddon, V. Parpura, Nano Lett. 2004, 4,
507.
[201] Y. Ni, H. Hu, E. B. Malarkey, B. Zhao, V. Montana, R. C. Haddon, V.
Parpura, J. Nanosci. Nanotechnol. 2005, 5, 1707.
[202] H. Hu, Y. Ni, S. K. Mandal, V. Montana, B. Zhao, R. C. Haddon, V.
Parpura, J. Phys. Chem. B 2005, 109, 4285.
[203] T. C. Pappas, W. M. S. Wickramanyake, E. Jan, M. Motamedi, M.
Brodwick, N. A. Kotov, Nano Lett. 2007, 7, 513.
[204] K. Wang, H. A. Fishman, H. Dai, J. S. Harris, Nano Lett. 2006, 6, 2043.
[205] C. J. Smith, B. J. Shaw, R. D. Handy, Aquat. Toxicol. 2007, 82, 94. 2009 WILEY-VCH Verlag Gmb[206] A. V. Liopo, M. P. Stewart, J. Hudson, J. M. Tour, T. C. Pappas, J. Nanosci.
Nanotechnol. 2006, 6, 1365.
[207] A. Helland, P. Wick, A. Koehler, K. Schmid, C. Som, Environ. Health
Perspect. 2007, 115, 1125.
[208] A. Mazzatenta, M. Giugliano, S. Campidelli, L. Gambazzi, L. Businaro, H.
Markram, M. Prato, L. Ballerini, J. Neurosci. 2007, 27, 6931.
[209] A. Huczko, H. Lange, Fullerene Sci. Technol. 2001, 9, 247.
[210] C. S. Sharma, S. Sarkar, A. Periyakaruppan, J. Barr, K. Wise, R. Thomas,
B. L. Wilson, G. T. Ramesh, J. Nanosci. Nanotechnol. 2007, 7, 2466.
[211] K. Pulskamp, S. Diabate, H. F. Krug, Toxicol. Lett. 2007, 168, 58.
[212] M. Bottini, S. Bruckner, K. Nika, N. Bottini, S. Bellucci, A. Magrini, A.
Bergamaschi, T. Mustelin, Toxicol. Lett. 2006, 160, 121.
[213] J. M. Worle-Knirsch, K. Pulskamp, H. F. Krug, Nano Lett. 2006, 6, 1261.
[214] N. A. Monteiro-Riviere, R. J. Nemanich, A. O. Inman, Y. Y. Wang, J. E.
Riviere, Toxicol. Lett. 2005, 155, 377.
[215] D. Pantarotto, J. P. Briand, M. Prato, A. Bianco, Chem. Commun. (Camb.)
2004, 16.
[216] D. Pantarotto, R. Singh, D. McCarthy, M. Erhardt, J. P. Briand, M. Prato, K.
Kostarelos, A. Bianco, Angew. Chem. Int. Ed. Engl. 2004, 43, 5242.
[217] A. Nimmagadda, K. Thurston, M. U. Nollert, P. S. McFetridge, J. Biomed.
Mater. Res. 2006, 76, 614.
[218] F. Tian, D. Cui, H. Schwarz, G. G. Estrada, H. Kobayashi, Toxicol. In Vitro
2006, 20, 1202.
[219] A. M. Rajnicek, S. Britland, C. D. McCaig, J. Cell Sci. 1997, 110, 2905.
[220] G. P. Dillon, X. Yu, R. V. Bellamkonda, J. Biomed. Mater. Res. 2000, 51, 510.
[221] G. Jia, H. Wang, L. Yan, X. Wang, R. Pei, T. Yan, Y. Zhao, X. Guo, Environ.
Sci. Technol. 2005, 39, 1378.
[222] P. Wick, P. Manser, L. K. Limbach, U. Dettlaff-Weglikowska, F. Krumeich,
S. Roth, W. J. Stark, A. Bruinink, Toxicol. Lett. 2007, 168, 121.
[223] P. M. Raja, J. Connolley, G. P. Ganesan, L. Ci, P. M. Ajayan, O. Nalamasu,
D. M. Thompson, Toxicol. Lett. 2007, 169, 51.
[224] D. H. Kim, D. C. Martin, Biomaterials 2006, 27, 3031.
[225] D. A. Eavarone, X. J. Yu, R. V. Bellamkonda, J. Biomed. Mater. Res. 2000,
51, 10.
[226] J. M. Saul, A. Annapragada, J. V. Natarajan, R. V. Bellamkonda, J. Control.
Release 2003, 92, 49.
[227] J. M. Saul, A. V. Annapragada, R. V. Bellamkonda, J. Control. Release 2006,
114, 277.
[228] J. Kreuter, Adv. Drug Deliv. Rev. 2001, 47, 65.
[229] Y. Xie, L. Y. Ye, X. B. Zhang, W. Cui, J. N. Lou, T. Nagai, X. P. Hou,
J. Control. Release 2005, 105, 106.
[230] D. Papahadjopoulos, T. M. Allen, A. Gabizon, E. Mayhew, K. Matthay, S. K.
Huang, K. D. Lee, M. C. Woodle, D. D. Lasic, C. Redemann, F. J. Martin,
Proc. Natl. Acad. Sci. USA 1991, 88, 11460.
[231] A. Weissenbock, M. Wirth, F. Gabor, J. Control. Release 2004, 99, 383.
[232] D. J. Bharali, I. Klejbor, E. K. Stachowiak, P. Dutta, I. Roy, N. Kaur, E. J.
Bergey, P. N. Prasad, M. K. Stachowiak, Proc. Natl. Acad Sci. USA 2005,
102, 11539.
[233] L. L. Zou, L. Huang, R. L. Hayes, C. Black, Y. H. Qiu, J. R. Perez-Polo, W.
Le, G. L. Clifton, K. Yang, Gene Ther. 1999, 6, 994.
[234] S. Jin, K. M. Ye, Biotechnol. Prog. 2007, 23, 32.
[235] A. Bianco, K. Kostarelos, M. Prato, Curr. Opin. Chem. Biol. 2005, 9, 674.
[236] C. E. Thomas, A. Ehrhardt, M. A. Kay, Nat. Rev. Genet. 2003, 4, 346.
[237] K. Yang, G. L. Clifton, R. L. Hayes, J. Neurotrauma 1997, 14, 281.
[238] J. Panyam, V. Labhasetwar, Adv. Drug Deliv. Rev. 2003, 55, 329.
[239] J. Kreuter, D. Shamenkov, V. Petrov, P. Ramge, K. Cychutek, C. Koch-
Brandt, R. Alyautdin, J. Drug Target 2002, 10, 317.
[240] W. Sun, C. Xie, H. Wang, Y. Hu, Biomaterials 2004, 25, 3065.
[241] W. Sun, H. Wang, C. Xie, Y. Hu, X. Yang, H. Xu, J. Control. Release 2006,
115, 259.
[242] G. Liu, P. Men, P. L. Harris, R. K. Rolston, G. Perry, M. A. Smith, Neurosci.
Lett. 2006, 406, 189.
[243] W. Lu, Y. Zhang, Y. Tan, K. Hu, X. Jiang, S. Fu, J. Control. Release 2005, 107,






www.advmat.de[244] W. Lu, Q. Sun, J. Wan, Z. She, X.-G. Jiang, Cancer Res. 2006, 66,
11878.
[245] N. Tagmatarchis, H. Shinohara, Mini Rev. Med. Chem. 2001, 1, 339.
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